Adrenal Incidentaloma

Mark Sherlock, Andrew Scarsbrook, Afroze Abbas, Sheila Fraser, Padiporn Limumpornpetch, Rosemary Dineen, and Paul M. Stewart

Abstract An adrenal incidentaloma is now established as a common endocrine diagnosis that requires a multidisciplinary approach for effective management. The majority of patients can be reassured and discharged, but a personalized approach based upon image analysis, endocrine workup, and clinical symptoms and signs are required in every case. Adrenocortical carcinoma remains a real concern but is restricted to <2% of all cases. Functional adrenal incidentaloma lesions are commoner (but still probably <10% of total) and the greatest challenge remains the diagnosis and optimum management of autonomous cortisol secretion. Modern-day surgery has improved outcomes and novel radiological and urinary biomarkers will improve early detection and patient stratification in future years to come. (Endocrine Reviews 41: 1 – 46, 2020)

Graphical Abstract

Key Words: adrenal adenoma, adrenal incidentaloma, adrenal computed tomodraphy, autonomous cortisol secretion, adrenal cortical carcinoma
The use of diagnostic imaging has increased dramatically over the last 3 decades, driven by several factors, including technological advancement in imaging modalities, growing awareness of preventive care, the rising number of diagnostic imaging centers, and increasing prevalence of chronic disease driven in large part by an aging population. According to estimates from the Organisation for Economic Co-operation and Development, in 2016, the United States performed 245 computed tomography (CT) scans per 1000 population compared with a mean of 151 per 1000 population across 11 other high-income countries (1). For magnetic resonance imaging (MRI) the figures were 118 per 1000 population in the US and 82 per 1000 in other countries (1). Therefore, approximately 80 million CT scans are performed each year in the US (2), and in the UK over 5 million CT scans were performed in 2018 (3). Improvements in imaging modalities and their increasing use have led to the increased discovery of unexpected pathological findings. One of the most common unexpected findings revealed by CT, MRI, or ultrasonography is an incidental adrenal mass or incidentaloma. An adrenal incidentaloma (AI) is defined as a clinically unapparent adrenal mass greater than 1 cm in diameter detected during imaging performed for reasons other than for suspected adrenal disease (4). The term “incidentaloma” was coined in 1982 by Geelhoed and Druy (5), who recognized that with the advent of improved resolution of radiological techniques clinicians were faced with the unfamiliar dilemma of early diagnosis of an asymptomatic adrenal mass. This strict definition, recognized by the European Society of Endocrinology and European Network for the Study of Adrenal Tumors (ESE/ENSAT), excludes adrenal lesions discovered during the screening of patients with hereditary syndromes or extra-adrenal tumors (4). Current guidelines do not recommend that incidentally discovered adrenal lesions with a diameter <1 cm undergo further investigation unless clinically indicated (4,6-8).

Prevalence and epidemiology of AI
The prevalence of AIs varies depending on the source of data (autopsy, surgery, or radiology series) and patient selection (from general or specialized units). In the autopsy series with large patient numbers (series with greater than 1000 patients) (9-16), the reported prevalence of AI ranges from 1.05% (9) to 8.7% (10) (Table 1 (9-31)). In a large retrospective Japanese study, Kobayashi et al. investigated all cases of primary adrenocortical tumors recorded in the Pathological Autopsy Case Annuals of Japan during the 12-year period from 1973 to 1984 (17) (n = 321 847 cases) and reported a significantly lower overall prevalence of 0.03% of adrenocortical adenomas compared with historical series; however, the prevalence increased with age, with a peak in the fifth and sixth decades. Of the total number of identified adenomas in this autopsy series (n = 101), only 25 were identified in patients <50 years, while the remaining 75% were identified in patients older than 50 years. The variability in reported prevalence among the postmortem series reflects a combination of patient selection, inclusion criteria and the diagnostic challenge of distinguishing nodular hyperplasia and small adrenal nodules or adenomas. There is some overlap in the literature between the terms adenoma and nodule. Some authors have tried to define and divide these further. Russell et al. used the terms “adenoma” and “nodule” interchangeably to describe grossly visible collections of adrenal cortical cells, without any strict measurement criteria, in an autopsy series of 35 000 cases (15). They reported an overall prevalence of adrenal cortical adenomas (of all sizes) of 1.73%, increasing to 3.03% in patients older than 20 years (15). In a further autopsy series of 498 cases, Reinhard et al. (30) reported a higher prevalence of 5% for adrenal adenomas.

Essential Points
- Adrenal incidentaloma (AI) is a common endocrine diagnosis affecting ~2% of the general population, but over 7% of those over 70 years. It is rare in subjects below 40 years of age
- ~2% of patients with AI have adrenocortical cancer
- Up to 10% of patients with AI have autonomous secretion of adrenal hormones
- The initial investigation of choice is an unenhanced computed tomography scan of both adrenal glands
- Pheochromocytoma and autonomous cortisol secretion should be excluded in every case and aldosteronism in patients with underlying hypertension and/or hypokalemia
- Most patients with AI can be discharged once malignancy and hormone hypersecretion have been excluded
- A causal link between cortisol hypersecretion and age-related comorbidities should be firmly established before recommending surgical excision
The prevalence of any disease increases with the observer's ability to detect the abnormalities associated with the disease (32). The first CT scan series regarding AIs, published between 1982 and 1986, reported a prevalence of 0.6% to 1.3% (33-35), which likely represents an underestimation due to the low-resolution technology available at the time and failure to detect smaller lesions. Over the last 2 decades, there has been a dramatic increase in the detection of AIs; series with contemporary high-resolution CT techniques report a prevalence close to that observed at autopsy (Table 2 (36-44)). In 2006, Bovio et al. (41) reported a frequency of AIs of 4.4% in a prospective study of 520 patients. This was significantly higher than the previous imaging series. While this increase may reflect improved modern scanning technology, the study included only patients older than 55 years of age, thereby only capturing patients at an age at which there is a greater prevalence of adrenal masses. Similarly, Song et al. reported a prevalence of 5% for AI in a retrospective study of CT reports (42). However, the study protocol included a dedicated radiological review of adrenal imaging in a significant percentage of cases, thereby possibly resulting in the diagnosis of more AI than would have been encountered in routine radiological clinical practice (44,45).

| Study/year (ref.) | Total no. of patients | Adenoma frequency (%) |
|-------------------|-----------------------|-----------------------|
| Rinehart et al. 1941 (18) | 100 | 3 |
| Dempsey 1942 (19) | 50 | 8 |
| Russi et al. 1945 (11) | 9000 | 1.45 |
| Commons and Callaway 1948 (12) | 7437 | 2.86 |
| Schroeder 1953 (13) | 4000 | 1.38 |
| Dawson 1956 (20) | 45 | 8.9 |
| Holmes et al. 1956 (21) | 53 | 1.9 |
| Shamma et al. 1958 (22) | 220 | 1.8 |
| Spain and Weisnsait 1964 (23) | 200 | 15.5 |
| Dévényi 1967 (14) | 5120 | 3.55 |
| Kokko et al. 1967 (9) | 2000 | 1.05 |
| Hedeland et al. 1968 (10) | 739 | 8.7 |
| Dobbie 1969 (24) | 50 | 32 |
| Yamada and Fukunaga 1969 (25) | 948 | 5.4 |
| Granger and Genest 1970 (26) | 2425 | 2.52 |
| Russell et al 1972 (15) | 35000 | 1.73 |
| Abecasssis et al 1985 (27) | 988 | 1.9 |
| Winkelmann et al. 1987 (28) | 117 | 3.4 |
| Meagher et al. 1988 (29) | 2951 | 5 |
| Kawano et al. 1989 (16) | 153000 | 0.24 |
| Kobayashi et al. 1991 (17) | 321847 | 0.03 |
| Reinhard et al. 1996 (30) | 498 | 5 |
| Sington et al. 1999 (31) | 29 | 6.9 |
| **Median values for all studies** | 948 | 3 |

Source data is highly variable in terms of autopsy, surgery or radiological in origin, patient selection and AI definition.
Effect of age, sex, and ethnicity on AI prevalence. Among autopsy and radiology series, the prevalence of AIs increases with age, showing a peak incidence in the fifth to seventh decades (Table 3 (39,40,42,46-84)). AIs are rarely seen in patients less than 30 years of age (66) and therefore if present should be investigated promptly due to the risk of adrenocortical carcinoma (ACC) or functional lesions. Previous imaging studies have reported that AIs are more common in females (66,71,73); however, this has not been observed in autopsy studies (11,85).

A recent large prospective Korean study, the COAR (the Co-work Of Adrenal Research) (81), investigated the characteristics of 1005 Korean patients with AIs and compared them with those of the largest previous retrospective study conducted in a Study Group on Adrenal Tumors of the Italian Society of Endocrinology cohort (66). The results showed some discordance between the patient cohorts. AIs in Korean patients were more frequent in men (57%) and the population was younger (median 55 years) than the Italian patient cohort. Also, fewer AIs underwent surgical resection in the Korean study. These differences likely reflect the different time period of the studies: the patients of the Italian study were recruited from 1980 to 1995, while those of the COAR were recruited from 2011 to 2014. The fact that fewer patients in the COAR study underwent adrenalectomy may be due to smaller adenoma size at discovery, an increase in the detailed characterization of AIs using improved imaging techniques (discussed in “Imaging Evaluation of an AI”), and endocrinological assessment (discussed in “Endocrine Work-up of AI”) leading to more reassurance regarding their benign nature. There has also been an increase in our knowledge concerning the natural history of untreated adrenal lesions and the recent development of international evidence-based management guidelines reflect this (4,6).

Size and lateralization of AI. A large number of clinical studies have investigated the characteristics of AIs (Table 3 (39,40,42,46-84)). The mean diameter of AI discovered by CT scan is 30 mm, ranging from 8 to 230 mm (Table 3 (39,40,42,46-84)) (the 8-mm lesions reflect the results of older studies before adopting 1 cm as the threshold for the definition of an AI). Many studies are limited by their retrospective nature, specialized center bias, patient selection bias, recall bias, and small sample size. However, it should be noted that all studies consistently report a higher incidence of ACC if the adrenal mass is greater than 4 cm in size (39,49,63,66,71).

The development of new CT protocols has improved the detection and characterization of adrenal masses (87). A similar distribution of lesions in the right and left adrenal gland has been reported
| Study (ref)            | Year | No. of patients | Mean Age (years) | Female/Male | Tumor size (median, mm) | Unilateral | Right | Left | Bilateral |
|-----------------------|------|-----------------|------------------|-------------|-------------------------|------------|-------|------|-----------|
| Virkkala et al. (46)  | 1989 | 20              | 59               | 1.4         | 23                      | 14         | N/A   | N/A  | 5         |
| Herrera et al. (39)   | 1991 | 342             | 62               | 1.5         | 25                      | N/A        |       |      |           |
| Aso and Homma (47)    | 1992 | 210             | 53               | 0.7         | 49                      | N/A        |       |      |           |
| Reincke et al. (48)   | 1992 | 68              | 59               | 1.6         | 32                      | N/A        |       |      |           |
| Caplan et al. (40)    | 1994 | 26              | 66               | 1.9         | NR                      | N/A        |       |      |           |
| Osella et al. (49)    | 1994 | 45              | 58               | 1.4         | 30                      | N/A        |       |      |           |
| Seppel and Schlaghecke (50) | 1994 | 52              | 56               | 1.7         | 30                      | N/A        |       |      |           |
| Ambrosi et al. (51)   | 1995 | 32              | 55               | 2.5         | 27                      | 27         | 22    | 5    | 5         |
| Bencsik et al. (52)   | 1995 | 63              | 27—85            | 1.1         | 14—25                   | N/A        |       |      |           |
| Flecchia et al. (53)  | 1995 | 32              | 57               | 1.3         | 37                      | N/A        |       |      |           |
| Bardet et al. (54)    | 1996 | 35              | N/A              | N/A         | 26                      | 35         | N/A   | N/A  | 0         |
| Linos et al. (55)     | 1996 | 57              | 49               | 1.3         | 59                      | N/A        |       |      |           |
| Bascounis et al. (56) | 1997 | 86              | 61               | 1.5         | 41                      | 81         | 45    | 36   | 5         |
| Bondanelli et al. (57) | 1997 | 38              | 58               | 1.4         | 26                      | 28         | 16    | 12   | 10        |
| Kasperlik-Zeluska et al (58) | 1997 | 208             | 52               | 2.5         | 8—210                   | 172        | 106   | 66   | 36        |
| Terzolo et al. (59)   | 1995 | 46              | 55               | 1.4         | 31                      | N/A        |       |      |           |
| Proye et al. (60)     | 1998 | 103             | N/A              | N/A         | 31                      | N/A        |       |      |           |
| Murai et al. (61)     | 1999 | 59              | N/A              | N/A         | 31                      | N/A        |       |      |           |
| Tütüncü and Gedik (62) | 1999 | 33              | 51               | 1.2         | 51                      | N/A        |       |      |           |
| Fawwa et al. (63)     | 2000 | 158             | 58               | 1.2         | 44                      | 158        | 74    | 84   | 0         |
| Mantero and Arnaldi (64) | 2000 | 208             | N/A              | N/A         | 31                      | N/A        |       |      |           |
| Rossi et al. (65)     | 2000 | 50              | 54               | 1.7         | 33                      | 47         | 28    | 19   | 3         |
| Mantero et al. (66)   | 2000 | 1004            | 58               | 1.4         | 30                      | 903        | 596   | 307  | 101       |
| Tanabe et al. (67)    | 2001 | 38              | N/A              | N/A         | 31                      | N/A        |       |      |           |
| Barzon et al. (68)    | 2002 | 284             | 56               | 1.5         | 36                      | N/A        |       |      |           |
| Bülow and Ahren (84)  | 2002 | 381             | 64               | 1.3         | 30                      | 359        | N/A   | N/A  | 22        |
| Tsvelev et al. (69)   | 2007 | 100             | 62               | 0.9         | 24                      | 77         | 34    | 43   | 23        |
| Study (ref)          | Year | No. of patients | Mean Age (years) | Female/Male | Tumor size (median, mm) | Unilateral | Right | Left | Bilateral |
|---------------------|------|----------------|------------------|-------------|-------------------------|------------|-------|------|-----------|
| Bhargav et al. (70) | 2008 | 53             | 41               | 1.1         | 78                      | 51         | 30    | 21   | 2         |
| Kasperlik-Zaluska et al. (71) | 2008 | 1444           | 10—87            | 2.7         | 10—230                  | 1175       | 709   | 466  | 269       |
| Song et al. (42)    | 2008 | 3307           | 64               | N/A         | 20                      | N/A        |       |     |           |
| Vassilatou et al. (72) | 2009 | 77             | 57               | 2.5         | 25                      | 59         | 22    | 37   | 17        |
| Comlekci et al. (73) | 2010 | 376            | 55               | 2.3         | 25                      | 313        | N/A   | N/A  | 54        |
| Anagnostis et al. (74) | 2010 | 64             | 62               | 1.9         | N/A                     | N/A        |       |     |           |
| Giordano et al. (75) | 2010 | 118            | 62               | 1.5         | 22                      | 102        | 57    | 45   | 16        |
| Yener et al. (76)   | 2010 | 317            | 55               | 2.7         | 24                      | 362        | 190   | 172  | 45        |
| Muth et al. (77)    | 2011 | 226            | 67               | 1           | 24.1                    | N/A        |       |     |           |
| Cho et al. (78)     | 2013 | 282            | 57               | 0.7         | 23                      | 261        | 103   | 158  | 21        |
| Di Dalmazi et al. (79) | 2014 | 129            | 61               | 1.5         | 21 (max)                | 92         | N/A   | N/A  | 22        |
| Hong et al. (80)    | 2017 | 1149           | 54               | 0.8         | 18                      | N/A        |       |     |           |
| Ahn et al. (81)     | 2018 | 1005           | 44               | 0.7         | 17                      | 902        | 308   | 594  | 103       |
| Akkus et al. (82)   | 2018 | 229            | 52               | 1.7         | 48                      | 202        | N/A   | N/A  | 27        |
| Goh et al. (83)     | 2018 | 228            | 61               | 1.5         | 18                      | 196        | 70    | 126  | 32        |
| **Median value for all studies** | | 64             | 57.5             | —           | 30                      | —          | —     | —    | —         |

Abbreviation: N/A, data not available.
in many CT series, in keeping with autopsy studies (Table 3). However, some studies suggest a higher prevalence of left-sided adrenal tumors detected on imaging (81, 88, 89), for example, the COAR study cohort described above (81). This observation may reflect a detection bias as left-sided adrenal tumors may be more readily apparent to the radiologist. Similarly, a recent large cross-sectional study of abdominal CT and MRI imaging in 1376 patients (90) reported a higher detection of left-sided adenomas than right-sided adenomas in each size category except when the tumor size was ≥30 mm. The authors concluded that this detection bias may result in under-recognition of small (<30 mm) right-sided lesions and bilateral disease (90).

Anatomy and Physiology of the Adrenal Gland

Anatomy of the adrenal gland
A brief overview of adrenal embryology, anatomy, physiology, and pathology is required to appreciate the clinical significance of AIs as it relates to the investigation and treatment of these lesions.

Historical perspective
The anatomy of the adrenal gland was first described by Bartholomeo Eustacius in 1563 and its functional importance subsequently elucidated by the pioneering work of Thomas Addison in 1855 (91). Shortly after Addison’s work, Brown-Séquard performed a series of bilateral adrenalectomies in several species of small animals and demonstrated that the adrenal glands are essential for life (92). Improvement in microscopy techniques in the nineteenth century helped describe the anatomy of the adrenals (Kölliker 1852), and the distinction between “cortical and medullary substances” (93).

Embryology and development
The adrenal gland is derived from 2 embryologically distinct origins with the adrenal cortex arising from the coelomic mesoderm of the urogenital ridge and the medulla from the neuroectoderm (neural crest cells) (92). The fetal adrenal gland is evident from 6 to 8 weeks of gestation and rapidly increases in size so that by midgestation it is larger than its adjacent kidney. In later stages of embryonic development, the cortex engulfs and eventually encapsulates the entire medulla. The adrenal cortex differentiates fully into its 3 constitutive zones (zona glomerulosa, zona fasciculata, and zona reticularis) by 3 years of age (94, 95) (Fig. 1).

The development of the adrenal cortex is dependent on the blood supply, paracrine adrenal factors, hormonal factors, and adrenocortical innervation (96). The nuclear receptor steroidogenic factor-1 (SF1 also known as NR5A1) is a pivotal factor for the initiation and fetal maturiation of the adrenal cortex (97), with its absence resulting in adrenal aplasia (98). An interplay

![Figure 1. Schematic diagram of the structure of the human adrenal cortex (92). Adapted from PM Stewart, Chapter 14 The Adrenal Cortex. In Williams Textbook of Endocrinology, 10th ed., Copyright © 2003 Elsevier Reproduced from Williams RH, Larsen PR. Williams Textbook of Endocrinology. 10th ed./ P. Reed Larsen...[et al.] ed. United States: Philadelphia : Saunders, ©2003. Copyright © 2003 Elsevier.]
between the transcription factors SF1 and an SF1 target gene, DAX 1, determines the extent to which steroidogenic enzymes are induced, and adrenocortical cells become differentiated (97). While adrenocortical growth and differentiation are independent of adrenocorticotropin (ACTH) during the first trimester of pregnancy, ACTH begins to play an essential role in the morphological and functional development of the adrenal gland after 15 weeks of gestation.

Structure, vasculature, and innervation of the adrenal gland

The adult adrenal gland is a pyramidal structure weighing approximately 4 grams, and is approximately 2 cm wide, 5 cm long, and 1 cm thick. It lies immediately above the kidney on its posteromedial surface (96). Although the left and right adrenal glands are symmetrical, the left gland is in a more caudal position, lying anteromedially to the left renal upper pole, laterally to the aorta and left diaphragmatic crus, and superior to the left renal vein (Fig. 2).

Beneath the adrenal capsule, the zona glomerulosa, constitutes approximately 15% of the mass of the cortex (depending upon salt intake), (Fig. 1 (92)). The zona fasciculata constitutes 75% of the cortex comprising lipid-laden cells that are larger than those in the zona glomerulosa, organized into bundles, leading to the origin of its name “fascicles.” The innermost layer of the adrenal cortex is the zona reticularis comprising irregular cells arranged as cords with little lipid content (92).

Though small, the adrenal glands have an extensive vasculature. This may account for the predilection of cancer metastases to the adrenal gland (101) and also for its susceptibility to nontraumatic adrenal hemorrhage (102). Three arteries supply each adrenal gland: the superior suprarenal artery from the inferior phrenic artery, the middle suprarenal artery directly from the abdominal aorta, and the inferior suprarenal artery from the renal artery. Blood is channeled into the subcapsular arteriolar plexus and subsequently distributed to the sinusoids, which in turn supply the adrenal cortex and medulla (96, 103) (Fig. 2). There are numerous variations of the venous drainage of the adrenal gland based on the adrenal and renal vein configurations and combinations, which have been extensively reviewed by Cesmebasi et al. (100). These variations are important both for the surgical management of adrenal lesions but also for diagnostic adrenal vein sampling (100).

Physiology of the adrenal gland

Functional zonation of the adrenal cortex. Aldosterone is the primary mineralocorticoid produced by the zona glomerulosa cells under the control of angiotensin II and extracellular potassium. The daily production rate of aldosterone varies between 80 and 200 μg/day (104), depending on daily

Figure 2. Anatomy of the adrenal gland. (i) Eustachio’s original drawing from Tabulae anatomicae published by Johannes Maria Lancisi in 1714 (99). (ii) The left adrenal–renal venous complex. The right adrenal vein (AV) drains directly into the IVC (100).
salt intake. Aldosterone functions as the ligand for the mineralocorticoid receptor in target tissues that include the colon, salivary gland, and the renal distal convoluted tubule and collecting ducts, where it causes increased reabsorption of sodium and increased excretion of both potassium (by principal cells) and hydrogen ions (by intercalated cells of the collecting duct). Aldosterone secretion is confined to the outer zona glomerulosa due to the restricted expression of \textit{CYP11B2}.

Glucocorticoids are secreted in relatively high amounts (cortisol 10-20 mg/day) from the zona fasciculata cells under the control of ACTH secreted from the anterior pituitary (92). In humans, cortisol is the main glucocorticoid produced by the adrenal cortex under normal conditions and its actions include mobilization of fats, proteins, and carbohydrates. Once produced and released into the bloodstream, glucocorticoids facilitate the release of energy stores for utilization during stress. Integral to the feedback control of the activated hypothalamic–pituitary–adrenal (HPA) axis, glucocorticoids inhibit the production and secretion of both corticotropin-releasing hormone (CRH) and ACTH from the HPA axis. As a class, adrenal androgens (dehydroepiandrosterone [DHEA], DHEA sulfate [DHEAS], and androstenedione) are the most abundant steroids secreted from the adult adrenal gland (>20 mg/day). DHEA is sulfated only in the zona reticularis to form DHEAS.

\textbf{Steroidogenesis.} Three main subclasses of steroid hormones are produced by the adrenal cortex: glucocorticoids (cortisol, corticosterone), mineralocorticoids (aldosterone, deoxycorticosterone [DOC]), and adrenal androgen and their precursors [mainly DHEA, DHEAS, and androstenedione] are the most abundant steroids secreted from the adult adrenal gland (>20 mg/day). DHEA is sulfated only in the zona reticularis to form DHEAS. Importantly, the functional zonation of the adrenal cortex is dependent upon the zonal expression of 2 key enzymes: the final step in cortisol biosynthesis involves the conversion of 11-deoxycortisol to cortisol by the enzyme 11\(\beta\)-hydroxylase (\textit{CYP11B1}), largely in the zona fasciculata. By contrast in the zona glomerulosa (although 11\(\beta\)-hydroxylase may also convert deoxycorticosterone to corticosterone) it is the enzyme \textit{CYP11B2} or aldosterone synthase that is uniquely required for the conversion of corticosterone to aldosterone through the intermediate 18-OH corticosterone.

\textbf{Physiology of the adrenal medulla.} Understanding the biosynthesis pathways, metabolism, and breakdown of catecholamines is crucial to understanding the biochemical assessment of pheochromocytomas and paragangliomas (107, 108). Briefly, the biosynthesis of catecholamines starts with the conversion of amino acid L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) by the enzyme tyrosine hydroxylase (TH). L-DOPA is converted to dopamine which is translocated to catecholamine storage vesicles of chromaffin cells of the adrenal medulla, sympathetic nerves, and paraganglia (Fig. 4 (108)). The enzyme dopamine-\(\beta\) hydroxylase is responsible for the conversion of dopamine into norepinephrine (noradrenaline). In adrenal medullary chromaffin cells, norepinephrine (noradrenaline) is further converted to epinephrine (adrenaline) by phenylethanolamine N-methyltransferase (Fig. 4 (108)). As this enzyme is only present in these cells, epinephrine (adrenaline) is almost exclusively produced within the adrenal medulla (108).

Catecholamines are metabolized through several pathways, resulting in numerous metabolites (Fig. 5). The majority of circulating norepinephrine (noradrenaline) is derived from noradrenergic neurons of the central and sympathetic nervous system (108). Deamination of neuronal norepinephrine (noradrenaline) to 3,4-dihydroxyphenylglycol occurs by monoamine oxidase. Norepinephrine (noradrenaline) is also partially metabolized in extraneuronal tissues and adrenal chromaffin cells, where it is converted to normetanephrine by catechol-O-methyltransferase (COMT) (108). Epinephrine (adrenaline) is mainly metabolized within adrenal chromaffin cells by COMT, resulting in the O-methylated metabolite metanephrine. Metabolism of dopamine follows other pathways, resulting in the production of the O-methylated metabolite methoxytyramine. Plasma free metanephrines are conjugated to sulfates by gut wall enzymes (108).
In patients with pheochromocytomas/paragangliomas, more than 90% of catecholamine catabolism occurs continuously within the tumor itself, mostly through the action of COMT (107). Elevated circulating levels of O-methylated metabolites, therefore, point to the presence of pheochromocytoma or paraganglioma with greater sensitivity and specificity than elevated levels of the parent amines. Elevation in amines may result from increased sympathetic nervous system activity or originate from other sources (107).

**Histology of adrenal tumors**

This has been extensively reviewed by Erickson et al. (109). In brief, there are several methods for immunophenotyping adrenal tissue and tumors. Both adrenocortical tumors and pheochromocytomas stain positive for synaptophysin but adrenocortical tumors are negative for chromogranin (109). S100 protein usually highlights sustentacular cells in pheochromocytomas and is negative in adrenocortical tumors. Adrenocortical tumors are also usually (but not always) positive (and pheochromocytomas negative) for Cytokeratin CAM 5.2, a-inhibin and calretinin. Steroidogenic factor 1 is increasingly recognized as a key marker of adrenocortical cell lesions (109).

Both adrenocortical cancers and melanomas stain positive for Melan A, but adrenocortical tumors are negative for S100 (a positive marker for melanoma). Additional markers may be required to exclude other primary lesions, for example, thyroid transcription factor 1 and cytokeratin.

**Differentiation of adrenocortical adenoma and carcinoma.** Although there are several clinical, endocrinological and radiological features that help risk stratify an adrenal lesion with regard to the likelihood of ACC (see "Etiology and clinical presentation of AI"), the final diagnosis is a histological one and requires the input of an experienced adrenal pathologist (110). The most widely used histological scoring system is the Weiss score (Table 4) based on 9 histological parameters (scored as 0 if absent and 1 if present) (110,111).
A threshold above a Weiss score of 3 (also on the modified score) was associated with an increased risk of malignant behavior (112). In the initial study by Weiss, the features with the strongest association to outcome were the mitotic rate >5/50 high powered field, atypical mitoses, and venous invasion (111) and in the second study by Weiss in 1989 the strongest association with patient outcome was the mitotic rate (112).

Another key predictor of malignant behavior is the Ki67 proliferative index (114). The cutoff at which a Ki67 labeling index confirms the diagnosis of ACC and predicts aggressive disease is debated and ranges from >2.5% to >7% (113,115-117). However, because of the enormous intratumoral heterogeneity of ACC, the site in which the Ki67 labeling index is obtained markedly influences the results. In particular, the question of whether the Ki67 labeling index should be calculated as the average of the entire tumor specimen or the summation of hot spots in the specimens has not been resolved (113). This limitation should be kept in mind when applying the Ki67 labeling index to categorizing and adrenal lesion and as a prognostic marker for ACC (113). The Helsinki score used in some centers incorporates the Ki67 labeling index and has been proposed to be a better predictor of outcome (118).

Pheochromocytoma of the Adrenal Gland Scaled Score and Grading of Adrenal Pheochromocytoma and Paraganglioma tool. In 2002 Thompson described a tool, Pheochromocytoma of the Adrenal gland Scaled Score (PASS), based on the presence or
absence of 12 specific histological features to allow better distinction between benign and malignant tumors (119). The histological features include vascular/capsular/periadrenal adipose tissue invasion, large nests or diffuse growth, focal or confluent necrosis, high cellularity, tumor cell spindling, cellular monotony, increased mitotic figures (>3/10 high power fields), atypical mitotic figures, nuclear pleomorphism, and hyperchromasia with weighted scores between 1 and 2. Tumors with a PASS score >4 were defined as having malignant potential, whereas those with a lower score were considered benign. Subsequent validation by a panel of experienced pathologists concluded that due to significant inter- and intraobserver variation PASS was not recommended for clinical prognostication (120).

Subsequently, Kimura et al. (121) developed a less involved scoring system for prediction of metastases, Grading of Adrenal Pheochromocytoma and Paraganglioma (GAPP) consisting of a smaller number of pathological parameters with weighted scoring (1 or 2 points) including histological pattern; cellularity; comedo necrosis; capsular/vascular invasion; Ki67 proliferative index; and catecholamine phenotype. A GAPP score of 0 to 2 is considered low risk, 3 to 6 intermediate risk, and 7 to 10 high risk. GAPP scoring was independently validated by Koh et al. and is considered a useful risk stratification tool for the prediction of metastatic potential (122).

Etiology and Clinical Presentation of AI

Many AIs, while picked up incidentally, may have clinical symptoms or associated signs on closer

![Diagram of catecholamine metabolism](https://example.com/catecholamine_diagram.png)
questioning and clinical examination. The etiology of an AI is variable and includes tumors from the adrenal cortex, the adrenal medulla, and metastatic deposits.

**Etiology: tumors of the adrenal cortex**

**Adrenocortical adenoma.** An ACA is a benign neoplasm of adrenocortical cells. The majority of these lesions are non-secretory; however, some may produce glucocorticoids independent of ACTH and mineralocorticoids independent of stimulation from the renin–angiotensin system. Rarely, they may also produce androgens or estrogens which may result in virilization or feminization. The 3′,5′-cyclic adenosine 5′-monophosphate–protein kinase A (cAMP–PKA) pathway is important for the regulation of adrenocortical cell development. ACTH binds to the ACTH receptor (a G-protein coupled receptor encoded for by the MCR2 gene) in the adrenocortical cell, thereby activating adenylyl cyclase, cAMP synthesis and activation of PKA. Abnormally increased cAMP–PKA signaling is thought to be the key mechanism in the development of most benign adrenocortical tumors (123).

**Cortisol-producing adenoma.** Autonomous cortisol secretion (ACS) (of variable clinical significance and severity) is frequently found in patients with an ACA. The majority of these cases are due to non-ACTH-dependent ACS from the adenoma. However, aberrant expression and activation of G-protein coupled receptors have been implicated as a possible mechanism explaining cortisol hypersecretion (and in primary hyperaldosteronism) (124, 125).

**ACC, adrenal lymphoma, and adrenal metastases.**

**Adrenocortical carcinoma.** Primary ACC is rare, with an estimated population incidence of 1 to 2 per million per year (126,127). Between 40% and 60% of ACCs are functional and may present with symptoms of hormonal hypersecretion (126,127,128,129), most commonly with Cushing’s syndrome (estimated 45%). Approximately 25% of ACCs will cosecrete glucocorticoids and androgens. Solely androgen-secreting ACCs are less common (approximately 10%), usually presenting with virilization without features of glucocorticoid excess. Feminization and hyperaldosteronism are rare occurring in <10% of cases (127,130). Importantly, if there is evidence of hypersecretion from 2 adrenal zones this is highly suggestive of an ACC as benign lesions do not secrete in this pattern.

Approximately 30% of ACCs present with symptoms of local mass effect, such as abdominal or flank pain. As ACCs are retroperitoneal they may present late and have often reached a large size (131).

The impact of the functional status and clinical features of ACCs on survival is unclear (132,133). However, cortisol hypersecretion leading to clinically evident Cushing’s syndrome is recognized as a significant cause of morbidity and mortality (134,135) due to increased risk of infection, metabolic, bone, and vascular complications (136).

Malignancy is also suspected based on imaging characteristics of the adrenal mass and size. The size of the adrenal mass is predictive (but not 100%) of malignancy. In an Italian study of 887 patients with AIs, 90% of ACCs had a diameter of greater than 4 cm at presentation, with a 4-cm cutoff having a 93% sensitivity for detecting ACC (64). Size at presentation may also impact prognosis from ACC, with a smaller size of tumor at diagnosis associated with a significantly higher 5-year survival (137). Imaging characteristics of adrenal lesions will be discussed in detail in “Imaging evaluation of an AI.”

Mutations in β-catenin (CTNNB1) leading to constitutive activation of the Wnt signaling pathway is a frequent finding in benign and malignant adrenocortical tumors (138). The Wnt signaling pathway is thought to be important in the embryonic development of the adrenal gland (139). Constitutive activation of this pathway is also implicated in cancer development in several other organs (140). In 1 study of 100 adrenal adenomas that had been surgically excised, 36%...
were found to contain CTNNB1 mutations (141). Somatic activating mutations of GNAS, which encodes the α-subunit of the stimulatory G protein (G,α), occur in 5% to 17% of adrenal adenomas which are cortisol secreting (142,143). An example of this is constitutive activation of adenyl cyclase as a result of somatic GNAS mutations in McCune–Albright syndrome (144).

Inactivating mutations in PRKAR1A have been described in cortisol-producing adrenal tumors. PRKAR1A gene encodes for a regulatory subunit of PKA, and inactivating mutations lead to constitutive activation of the cAMP–PKA pathway. Although mutations in this gene were first described in Carney complex (145), somatic mutations of PRKAR1A have been described in some sporadic adrenocortical tumors (146).

Somatic activating mutations of protein kinase A catalytic subunit (PRKACA) has been implicated in up to 50% of patients with adenomas with clinical Cushing’s syndrome, but not in adenomas producing less cortisol (138,142,147). Mutations in PRKACA may be associated with smaller adenomas but higher levels of cortisol production than adenomas where this mutation is not present (143,148). The lower frequency of these mutations in adenomas which produce less cortisol may be an explanation for the lack of progression in these patients to a clinically apparent Cushing’s syndrome.

Mutations in cyclic nucleotide phosphodiesterase have also been noted in cortisol-producing ACAs. These are enzymes that breakdown cyclic nucleotides and as a consequence regulate cAMP levels and cAMP–PKA pathway activity. Mutations in PDE11A and PDE8B genes are the most commonly reported (149,150).

**Aldosterone-producing adenoma.** Mutations in KCNJ5 (potassium channel) have been documented in patients with aldosterone-producing adenomas in approximately 40% of patients (151) from European cohorts, though much higher rates are reported in patients from Japan and Asia (152,153). These mutations lead to increased sodium conductance and cellular depolarization leading to calcium influx, increased intracellular calcium signaling, and increased CYP11B2 mRNA expression with increased aldosterone production and glomerulosa cell proliferation (123). Adenomas with KCNJ5 mutations tend to be larger than those which do not carry the mutation and appear to be more common in women than men (154).

Other somatic mutations in several of the genes involved in the regulation of aldosterone production have also been identified (155). In aldosterone-producing adenomas that did not have KCNJ5 mutations, abnormalities in ATP1A1 (encoding a Na+/K+ ATPase α subunit) were found in 5.2% and of ATP2B3 (encoding a Ca2+ ATPase) in 1.6%, with these mutations associated with increased plasma aldosterone concentrations and lower potassium concentrations than cases without the mutation (156). Additionally, mutations in the CACNA1D gene have been identified and recently gain of function mutations in the CLCN2 chloride channel gene (157) has also been described. This gene encodes a voltage-gated calcium channel and 11% of aldosterone-producing adenomas without mutations in KCNJ5 have been reported to carry mutations in this gene (158). Mutations in KCNJ5, CACNA1H, ATP1A1, ATP2B3, and CACNA1D account for approximately 50% of aldosterone-producing adrenal adenomas (159) in patients from Europe; this is likely to be higher in Asian patients.

**Adrenocortical carcinoma.** ACC is rare and aggressive and can occur at any age. However, peak incidence tends to be before the age of 5 and between the ages of 40 and 60 years of age (126,127). Most cases of ACC are sporadic but some are known to occur with other tumor syndromes (160). The most well known of these are Li–Fraumeni syndrome (TP53 gene), Multiple Endocrine Neoplasia type I (MEN1 gene) and Beckwith–Weidemann syndrome (abnormalities in 11p15I gene). The genetic mutations in these syndromes are well characterized. ACCs have also been noted in familial adenomatous polyposis (FAP gene), neurofibromatosis type 1 (NF1 gene), and Carney complex (PRKAR1A gene) (161).

In contrast, the genetic basis for sporadic ACCs is less clear. Loss of heterozygosity of chromosome 17p13, which codes for the tumor suppressor gene TP53, is a common finding in sporadic ACCs (162). However, only one-third of these ACCs have a mutation of TP53 (163). As previously described, mutations in CTNNB1 are also present in ACCs and may be associated with poor outcome (164). ZNRF3 is thought to be a tumor suppressor gene related to the β-catenin pathway, encoding a cell surface E3 ubiquitin ligase. Mutations in this gene were identified in 21% of 123 ACCs following genomic characterization (165).

Loss of heterozygosity at the 11p15 locus can lead to insulin-like growth factor-2 overexpression which is associated with malignant ACCs (166,167). Pan-genomic characterization of ACCs has identified several other driver genes including...
**CDKN2A, RB1, DAXX, TERT, MED12, PRKAR1A, RPL22, TERF2, CCNE1, and NF-1 (165,168).**

**Bilateral adrenocortical tumors.** Although the majority of AIs are unilateral, bilateral AIs may be found in 10% to 15% of cases (169). Two large studies (169,170) found that the most common causes of bilateral AI were metastasis, primary bilateral macronodular adrenal hyperplasia (PBMAH), and bilateral cortical adenomas. Other causes of bilateral AI include bilateral pheochromocytomas, congenital adrenal hyperplasia (CAH), Cushing’s disease, or ectopic ACTH secretion with secondary bilateral adrenal hyperplasia.

Bilateral adrenal hyperplasia is characterized by a nodule diameter of less than 1 cm (micronodular) and greater than 1 cm (macronodular). Primary pigmented nodular adrenocortical disease is characterized by multiple pigmented micronodules and does not usually present as an AI, and therefore will not be discussed further in this review.

PBMAH presents on imaging with characteristic multiple bilateral macronodules. Whole-genome sequencing, along with single nucleotide polymorphism array analyses, identified recurrent mutations in an armadillo repeat containing gene, located in chromosome 16p, in 50% of BMAH patients who underwent surgery (171). Patients with ARMC5 mutations tend to display adrenal hyperplasia associated with multiple nodules (172-175). Discovering ARMC5 mutations was the first evidence of BMAH as a genetic disease. ARMC5 is a putative tumor suppressor, with 2 hits in each adrenal nodule: a first germline alteration, found in leukocyte DNA and common to all nodules, and a second somatic hit (171). The penetrance of ARMC5 mutations is variable (172). ARMC5 overexpression induces apoptosis in vitro and its inactivation decreases steroidogenesis (171). The pathophysiology of BMAH is discussed further in “Bilateral AI and ACS.”

**Etiology: tumors of the adrenal medulla**

Tumors that originate from the chromaffin cells of the adrenal medulla, which secrete catecholamines, are termed pheochromocytomas. They may be benign or malignant. They can occur at any age, although are most common in the fourth to the fifth decade (176). The annual incidence of pheochromocytoma is estimated at 0.8 per 100 000 person-years (177). It is estimated 40% of catecholamine-secreting tumors are part of a hereditary syndrome and many endocrinologists are now offering genetic analysis to all affected cases. Von Hippel Lindau (VHL), multiple endocrine neoplasia ( MEN) type 2, and NF1 are the most well known of these and all have an autosomal dominant inheritance.

Other mutations have been associated with sporadic pheochromocytoma clustering to 2 common pathways: hypoxic signaling and kinase signaling genes. Affected genes in cluster 1 (hypoxic pathway) include subunits of succinate dehydrogenase (SDHD, SDHC, SDHB, SDHA, SDHAF2), HIF-1alpha, EGLN1/2, and KIF1B in addition to VHL. Cluster 2 genes code for activating proteins in kinase signaling and include NF1, RET, MAX, and TNEM127. Cluster 2 gene mutations are more likely to result in adrenal pheochromocytomas, whereas those in Cluster 1 mostly result in extra-adrenal noradrenergic paragangliomas (except for mutations in VHL). Mutations in VHL, RET, NF1, SDHB, and SDHD account for 90% of all pheochromocytomas and paragangliomas (123).

Hereditary pheochromocytomas tend to be diagnosed at a younger age, because of routine biochemical screening or genetic testing and are also more likely to be bilateral. In contrast, sporadic pheochromocytomas may be discovered incidentally on adrenal imaging (178,179). SDHB (10.3%) and SDHD (8.9%) mutations are the most frequent germline mutations in pheochromocytoma and paragangliomas (180).

The relative production of plasma metanephrine compared with plasma normetanephrine and methoxytyramine may help distinguish the genetic etiology of pheochromocytoma. In 1 large study of patients with pheochromocytoma and/or paraganglioma, patients with NF1 and MEN2 mutations could be discriminated from those with VHL and SDH mutations in 99% of cases by the relative concentrations of normetanephrine and metanephrine, as all patients with NF1 and MEN2 presented with tumors characterized by increased plasma concentrations of metanephrine, in contrast to patients with VHL and SDH mutations, usually presenting with increases in normetanephrine or methoxytyramine. Additionally, measurements of plasma methoxytyramine discriminated patients with SDH mutations from those with VHL mutations in a further 78% of cases (181).

**Clinical presentation of AI**

By definition, an AI is discovered when imaging is performed for another indication without any obvious clinical features of adrenal disease. However, on closer history and examination following the discovery of the adrenal lesion, there
may be features suggestive of adrenal disease. In cases where an adrenal mass is large (causing local pressure effect) or the tumor demonstrates clinically significant hormone hypersecretion, specific clinical features may be uncovered. However, it is important to note that even functional tumors may not result in significant clinical symptoms. Imaging characteristics cannot reliably distinguish between functional and nonfunctional tumors. As such, all patients with an AI should be systematically assessed for functional activity by endocrine biochemical testing, regardless of the presence or absence of symptoms (4).

**Adrenal lymphoma.** Adrenal gland involvement is well recognized and seen in up to 25% of patients with non-Hodgkin lymphoma usually as part of disseminated disease (182). Conversely primary adrenal lymphoma is much rarer accounting for <1% of all cases of non-Hodgkin lymphoma (183). Primary adrenal lymphoma usually manifests as a large well-defined mass with homogeneous enhancement and may invade into surrounding structures and biopsy may be required to differentiate from other more common tumors (184).

**Adrenal metastases.** A metastatic tumor is a common finding in the adrenal gland at post-mortem and the predilection of the adrenal gland for metastatic deposits is thought to be due to its extensive sinusoidal blood supply (185). In one series of 464 patients with metastatic adrenal gland lesions, 90% were carcinomas, with the others being hematological, sarcomas, or melanomas. Of the carcinomas, the most common primary site in 35% of cases was lung, followed by gastrointestinal, kidney, and breast. Interestingly, bilateral adrenal involvement was noted in almost half the patients in this case series (186). Adrenal metastases occur late in the course of disseminated cancers, and the primary site is usually already known.

Rarely metastatic adrenal tumors may lead to adrenal insufficiency, particularly in the context of large bilateral adrenal lesions (187). Therefore, in these circumstances, patients may present with symptoms and signs of adrenal insufficiency (fatigue, anorexia nausea, vomiting, postural hypotension, hyponatremia, and hyperkalemia). However, some of these clinical features are often difficult to distinguish from those of progressive metastatic malignancy.

**Functional AI.** Ten to 15% of AIs secrete hormones in excess (170). The clinical features ascribed to functional AI will be discussed in “Endocrine work-up of AI.”

**Endocrine Work-up of AI**

Clarification of the endocrine status of patients with AI is a cornerstone of management alongside the exclusion of malignancy. Clinical signs and symptoms of hormone excess and associated comorbidities together with a biochemical evaluation underpins personalized management. As a general principle, every patient with AI should be screened for adrenal catecholamine (although recent data has suggested this may not need to be the case in low Hounsfield unit lesions (188)) and glucocorticoid excess. Mineralocorticoid excess should be excluded in patients with hypertension and/or hypokalemia. Hirsutism or virilization or suspicion of an ACC should prompt measurement of androgens and gynecomastia estrogens.

**Screening for pheochromocytoma**

Pheochromocytoma may present incidentally, but on closer questioning, approximately 50% of cases have classical paroxysmal symptoms of sweating, headache, and tachycardia (189). Additionally, the diagnosis may be suspected if there is a family history of a heritable disorder commonly associated with pheochromocytoma as discussed in “Etiology and clinical presentation of AI.” Hypertension is a common sign of pheochromocytoma, but 5% to 15% of patients may have normal blood pressure at presentation, particularly in those with incidentaloma or having familial screening where the tumor may be smaller and less functionally active at presentation (190). Paradoxically, tumors that secrete only epinephrine may cause hypotension (191). Headache occurs in up to 90% of symptomatic patients (190) with sweating in 60% to 70%. Other symptoms include tremors, weakness, palpitations, anxiety, constipation, visual blurring, hyperglycemia, polyuria, and polydipsia (192).

Catecholamine-induced cardiomyopathy related to pheochromocytoma may present with signs of heart failure such as pulmonary edema (193). Rarely patients may also present with “pheochromocytoma crisis,” with hypertension or hypotension, multiorgan failure, psychiatric disorder, and hyperthermia (194).

Patients with familial pheochromocytoma may be asymptomatic in 50% of cases, with only a third presenting with hypertension, possibly representing earlier diagnosis and smaller lesions as a result of regular screening in these patients (195,196). While evaluation for catecholamine excess is recommended by ESE/ENSA guidelines in all AI patients (4), it may be possible to omit this in lipid-rich cortical adenomas. As discussed
in detail in “Imaging evaluation of an AI,” an unenhanced/noncontrast CT is recommended as the first-line investigation to confirm if an AI is homogeneous and to calculate the attenuation value measured in Hounsfield units (HU). A HU ≤ 10 is consistent with a benign adrenal adenoma or other benign lesions (eg, myelolipomas, lipomas). Mean HU scores for pheochromocytoma are 30 to 35 (197) with only 0.5% of pheochromocytoma having an unenhanced CT attenuation of ≤10 HU (97,197,198). Buitenwerf et al. (197) reviewed the CT images of 222 histologically proven pheochromocytomas, yielding only a single tumor with an unenhanced attenuation of <10 HU. Canu et al. (188) identified 2 (0.5%) of 376 histologically proven pheochromocytomas with unenhanced CT attenuation value of exactly 10 HU, 99.5% (n = 374) had a HU > 10. Despite the inherent drawbacks of the retrospective study design which include variable radiological techniques and selection of the region of interest, unenhanced attenuation is a valuable tool to distinguish lipid poor adenomas from pheochromocytomas. Set against this are the inherent risks of a missed diagnosis and prolonged exposure to catecholamines and cardiovascular morbidity/mortality (199,200). Additional pointers for considering biochemical testing in a patient with an unenhanced CT attenuation of ≤10 HU for pheochromocytoma are elderly patients (4), heterogeneity, or evidence of tumor necrosis.

Biochemical testing for pheochromocytoma has an excellent negative predictive value of 0.99. As described above in “Anatomy and physiology of the adrenal gland,” measurement of the O-methylated metabolites of catecholamines is now the main focus for specific measurement in an era of advanced analytics employing liquid chromatography tandem mass spectrometry (LC-MS/MS) (201). Plasma free or 24-hour urine fractionated metanephrines are recommended as the screening test of choice for pheochromocytoma with a sensitivity of 90% to 95% (202, 203). Specificity rates of 85% to 89% decrease to 77% in elderly people and can be improved by using age-adjusted reference ranges (204-206). Similarly, false positives can occur with concomitant medications such as sympathomimetic drugs or interfering substances including caffeine; avoiding these for 24 hours before testing is recommended (108,207,208). For plasma free metanephrines, blood is drawn after resting in the supine position at least 30 minutes (209) into prechilled heparinized tubes (108, 210). For 24-hour urine estimation, the use of acidified containers (to achieve urine pH <4) and storage in a cold place is recommended; measurement of creatinine is often used to ensure adequate collection (108,202,211).

**Screening for autonomous cortisol secretion**

The clinical features of Cushing’s syndrome are well defined; while individual susceptibility varies, generally, these are dictated by the degree and duration of cortisol hypersecretion. In many cases of AI with documented autonomous cortisol hypersecretion (ACS), cortisol secretion rates may not be significantly elevated. As a result, the patient may be asymptomatic, have no clinical features and have few comorbidities that may be ascribed to cortisol hypersecretion.

With nonspecific and wide-ranging signs and symptoms, diagnosing cortisol excess in patients with AI, particularly at levels that may be only marginally above “normal,” is challenging. For patients with overt Cushing’s syndrome, the Endocrine Society recommends the use of 2 of 3 highly sensitive screening tests: 24-hour urine free cortisol (UFC) excretion, late-night salivary cortisol (LNSC) levels and 9 am plasma cortisol following an overnight dexamethasone suppression test (1-mg dexamethasone suppression test [DST]; or low-dose DST) (212). Different assays (radioimmunoassay (RIA), enzyme-linked immunosorbent assay, automated chemiluminescence, high-performance liquid chromatography or mass spectrometry), patient comorbidities causing physiological hypercortisolism, and pseudo-Cushing’s syndrome are all confounding factors in the assessment of cortisol excess in patients with AI (212-214).

ACS is defined as an alteration of the HPA axis characterized by ACTH independent cortisol excess often without clinical signs and symptoms of overt Cushing’s syndrome. Nomenclature around this term has caused confusion with multiple names being given to this phenomenon including “subclinical Cushing’s syndrome,” “subclinical hypercortisolism,” and “preclinical Cushing’s syndrome” have all been used. However, we suggest the universal adoption of the term “autonomous cortisol secretion” as proposed by ESE/ENSAT (4). Despite the absence of florid signs and symptoms, ACS in patients AI has been associated with hypertension (215), insulin resistance (216), type 2 diabetes mellitus (217), obesity (218), metabolic syndrome (219), and increased mortality (75). ACS has emerged as the commonest functional abnormality in patients with AI with prevalence rates of up to 20% (64,65,72).

As highlighted through a summary of published guidelines, there is no gold standard test for diagnosing ACS. As can be seen in Table 5
Table 5. Summary of published guidelines for the diagnosis of subclinical Cushing’s syndrome (SCS)/autonomous cortisol secretion (ACS) in patients with AI.

| Guideline (year) (ref.) | NIH (2003) (221) | Endocrine Society (2008) (212) | AACE/AAES (2009) (86) | FSE (2008) (7) | IACE (2011) (222) | ESE/ENSAT (2016) (4) | Korea (2017) (223) | JES (2018) (224) |
|------------------------|------------------|-------------------------------|-----------------------|----------------|-------------------|---------------------|-------------------|-----------------|
| Terminology            | SCS              | SCS                           | ACS                   | Asymptomatic hypercortisolism | SCS               |                     |                   |                 |
| Country                | USA              | USA                           | USA                   | France         | Italy             | Europe              | Korea             | Japan           |
| First screening test   | (cut-off)        |                               |                       |                |                   |                     |                   |                 |
| 1-mg DST cut-off point | Yes >5 µg/dL; possible SCS | Yes >1.8 µg/dL | Yes >5 µg/dL | Yes >1.8 µg/dL; exclude >50 µg/dL; indeterminate | Yes <18 µg/dL; exclude >50 µg/dL; ACS 18–50 µg/dL; possible ACS | Yes <18 µg/dL; normal >50 µg/dL; asymptomatic hypercortisolism 18–50 µg/dL; additional testing | Yes >5.0 µg/dL ≥3 µg/dL; with (any of A–D) or E ≥1.8 µg/dL with (A and B) or E |
| Late night salivary cortisol | NM               | Yes (> 145 ng/dL) | NR                     | NR              | NR                | NM                  | NR                |                 |
| Second screening test  |                   |                               |                       |                |                   |                     |                   |                 |
| 24-hour UFC            | NM               | NR                            | NR                     | Yes            | Yes               | Yes (if 1mg DST > 5ug/dL) | Not recommended |
| Late-night serum cortisol | NM               | NM                            | NM                     | Yes            | Yes               | NM                  | NM                | Serum 2.100–2400 ≥5 µg/dL |
| ACTH                   |                   |                               |                       |                |                   |                     |                   | Yes             |
| Late-night salivary cortisol | NM               | NM                            | NR                     | NM              | NR                | Yes (if 1mg DST > 5ug/dL) | NM               |                 |
| 4-mg DST               | NM               | NM                            | NM                     | NM              | NR                | Yes (if 1mg DST > 5ug/dL) | NR               |                 |
| Confirmatory test      |                   |                               |                       |                |                   |                     |                   |                 |
| 4-mg DST               | NM               | NR                            | Yes                    | NM              | NR                | NM                  | NR                |                 |
| 8-mg DST               | NM               | NR                            | NM                     | NR              | NM                | NM                  | NR                |                 |
| Localization (adrenal in origin) |                   |                               |                       |                |                   |                     |                   |                 |
| ACTH                   | NM               | Yes                           | Yes                    | Yes             | Yes               | Yes                 | <10 pg/mL         |                 |
| DHEA-S                 | NM               | Yes                           | Yes                    | NR              | NR                | NM                  | NM                |                 |
| 4-mg DST               | NM               | NM                            | NM                     | NM              | NM                | NM                  | NM                |                 |
there is a wide variety of first screening, secondary screening and confirmation tests depending on the guideline. The sensitivity and specificity of these tests in patients with ACS have also been widely reported and are summarized in Table 6. Overall, the consensus from these recommendations supports the use of the 1-mg DST as having the highest sensitivity for screening for ACS, Table 6. A post-dexamethasone cortisol level ≤1.8 μg/dL (≤50 nmol/L) is considered “normal” and excludes cortisol excess in most patients. Levels between 1.9 and 5.0 μg/dL (50-140 nmol/L) may indicate “possible autonomous cortisol secretion,” and cortisol levels above 5.0 μg/dL (140 nmol/L) are suggested to confirm ACS (79,220). Sensitivity increases as the stringency of the “cut-off” is lowered; from 80% at a cut off of 140 nmol/L to 95% at 50 nmol/L, but this is offset by lower specificity, such that at a cut off of 50 nmol/L 20% of the “normal” population will fail to suppress cortisol. Even at a cut-off concentration of 140 nmol/L specificity is only 95%; the investigator must consider that a false positive result is far more likely than a true positive (45). Furthermore, many of the age-related comorbidities ascribed to ACS (notably obesity, diabetes, anxiety/depression—see later) are in themselves causes of physiological hypercortisolism, and therefore confirming a diagnosis and ascribing clinical features to ACS that might prompt surgical intervention remains a major challenge.

UFC in isolation has a low sensitivity (31.8-76.0%) in diagnosing ACS but this can be improved by LC-MS/MS methodology (sensitivity 98%, specificity 91%, and negative/positive likelihood ratios of 0.02/10.83, respectively). A combination of the 1-mg DST with UFC decreases the false positive rate further (239). LNSC is emerging as perhaps the most accurate test in diagnosing overt Cushing’s syndrome (240), but for ACS the published studies have given mixed results. In some cases, sensitivity reached 93.8%, but with relatively poor specificity at 79.5% (227) (Table 6).

An Italian study diagnosed ACS based on 2 out of the following 3 tests: serum cortisol >3 μg/dL (83 nmol/L) after 1 mg of ONDST; UFC >70 μg/24 hours (193 nmol/24 hours) or ACTH <10 pg/mL (2.2 pmol/L) (228). While this was put forward as a way of improving accuracy, it also increases the likelihood of a false positive result and is not our usual practice. Intuitively a low/suppressed ACTH would seem a sensible adjunct in the diagnosis of ACS (Tables 5 and 6).

**Clinical consequences of ACS—cardiometabolic and bone.** Based on the established clinical
Table 6. Summary of published data on diagnostic screening tests for investigating autonomous cortisol secretion and Cushing’s syndrome in patients with adrenal incidentaloma.

| Test               | Cut-off               | CS                 | ACS or mild CS or occult CS |
|--------------------|-----------------------|--------------------|----------------------------|
|                    | Sensitivity (%)       | Specificity (%)    | False positive (%)         | False negative (%) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Ref. |
| 1-mg DST           | 1.8 µg/dL (50 nmol/L) | 95-100             | 60-80.2                    | 8                  | 0               | 75-100           | 62–72   | 59      | 100 (225,226) |
|                    | 2.0 µg/dL             |                    |                             |                    |                 | 91.3             | 56.3    |         | (68,230231) |
|                    | 2.2 µg/dL             |                    |                             |                    |                 | 100              | 67      |         | (230231) |
|                    | 3 µg/dL (86 nmol/L)   | 100                | 91.8                        | 3                  | 12-15           | 52.4-86.4        | 52.4-96.3 |         | (230231) |
|                    | 5 µg/dL (138 nmol/L)  | 86.5               | 92-97.4                     | 3                  | 12-15           | 44–83.3           | 83-100  | 57      | 95 (64,68,227,228,230231) |
| LNSC               | 2.7 nmol/L (RIA)      | 97                 | 77                          | (232)              |                 | 31.3             | 83.3    |         | (233) |
|                    | 2.8 nmol/L (LC-MS/MS) |                    |                             |                    |                 | 93               | 91      |         | (234) |
|                    | 100 ng/dL (2.76 nmol/L) |                    |                             |                    |                 | 93               | 91      |         | (234) |
|                    | 0.350 µg/dL           | 92                 | 100                         | (232)              |                 | 93.8             | 79.5    |         | (227) |
|                    | 3.6 nmol/L (RIA)      | 92                 | 100                         | (232)              |                 | 2.27             | 87.7    |         | (235) |
|                    | 5.1 nmol/L            | 100                | 100                         | (226)              |                 | 22.7             | 87.7    |         | (235) |
|                    | 14.46 nmol/L          | 86 (73–93)         | 92 (86–95)                  | (228)              |                 | 100              | 91.1    |         | (236) |
| 24-h UFC           | 80 µg (170 nmol) or ULN | 91-96             | 896-925                     | 8                  | 2               | 318-76           | 80-100  | 49 (100) | 96 (93.3) | (227,228) |
| DHEA-S ratio       | 12                    |                    |                             |                    |                 | 100              | 91.1    |         | (236) |
| ACTH               |                       |                    |                             |                    |                 | 41-86.4          | 38-96   | 47      | 96 (64,230) |
| Midnight serum cortisol | 18 µg/dL (50 nmol/L) | 99-100             | 202                         | (225)              |                 | 22.7             | 87.7    |         | (64) |
|                    | 5 µg/dL (135 nmol/L)  | 95-100             | 739                         | (225)              |                 | 77               | 68      |         |         |
|                    | 75 µg/dL              | 90-96              | 87.7                        | (225)              |                 |                  |         |         |         |
| Plasma steroid metabolomic |               | Sensitivity 97 AUC 0.991 | (237) |
features of overt Cushing's syndrome, there is now an extensive literature on the potential clinical impact of more modest increases in cortisol secretion as seen in ACS.

This has been reviewed extensively in focused articles on "subclinical Cushing's" (now termed ACS) (241-245). In brief, cardiovascular morbidity includes increased left ventricular hypertrophy and arterial stiffness (246), hypertension, coronary heart disease, stroke, and fatal or nonfatal myocardial infarction. ACS is associated with mild to moderate hypertension in 41% to 92% of cases (47). A recent systematic review showed that ACS patients had a higher prevalence of cardiovascular events (16.7-26.8%) compared with patients with nonfunctional AI (6.7-10.4%) (79,244,245,247). Increased cardiovascular disease has been linked to the post-1-mg DST cortisol level as an independent cardiovascular risk factor (245). A study with up to 15 years of follow-up in patients with ACS has documented increased cardiovascular morbidity (43% vs 8.8%, \( P < .005 \)) and mortality (22.6% vs 2.5%, \( P < .02 \)) in ACS patients compared with nonfunctioning AI. Pulmonary infection and cardiovascular complications were the major causes of death (220,247).

It is well established that glucose intolerance and diabetes mellitus are prevalent features of overt Cushing's syndrome (228,248). Impaired glucose tolerance or diabetes has been reported to occur in 10% to 69% of patients with ACS (249) and improved glycemic control (and in some cases reversal of diabetes) following surgery is reported in some studies but not others (Table 7).

Similarly, the deleterious effects of chronic glucocorticoid excess on bone mineral density leading to osteoporosis are well established (258). However, in patients with ACS, a mixed picture is reported with either decreased, normal, or even increased bone formation reported alongside normal bone resorption (229,242,259-262). This variance is likely to be explained by differences in bone turnover markers studied, underlying vitamin D, parathyroid hormone concentrations, age, sex (notably the percentage of postmenopausal women), and the sample size. Cortisol affects trabecular bone to a greater degree than cortical bone, which is similar to the postmenopausal state. Both trabecular (65,261-263) and cortical (259,262,264,266) bone loss have been described in patients with ACS. For bone fracture, a meta-analysis reported a prevalence of vertebral fracture in patients with ACS of 63.6% (95% CI 55.98-71.26%) (254) and this risk is independent of age, sex, gonadal status, or bone mineral density (264).
Reversal of ACS. Several studies have reported the outcome of surgical intervention but most involve small numbers and are retrospective, uncontrolled, and lack randomization (230,243,250-253,255). ClinicalTrials.gov lists several prospective trials that are underway but are yet to report.

Metabolic improvement after adrenalectomy, including weight loss, blood pressure lowering, glucose tolerance, lower lipids, and beneficial effects on bone have been reported (230,267). A recent systematic review addressed cardiovascular benefit in ACS patients (247) with adrenalectomy improving cardiovascular outcome and mortality (4,247).

In the absence of a robust evidence base for the surgical treatment of ACS and reversal of symptoms and signs, establishing a causative link of ACS to cardiometabolic traits that increase naturally with age and low bone mineral density remains a challenge. It is reasonable to assume that patients, albeit with mild forms of adrenal Cushing’s syndrome, should benefit from surgery, noting that even in patients with established Cushing’s syndrome, the reversal of the clinical phenotype can take many months or years. The degree of hypercortisolism within the ACS definition, the severity of clinical features detailed earlier, balanced against risks of surgery in an aged population must be considered as an individualized approach. The real risk is an unnecessary procedure for an elderly patient with coincidental age-related comorbidities that have no causal relationship to adrenal Cushing’s syndrome (hypertension, diabetes, glucose intolerance, weight, and reduced bone mass) in patients with AI. This will likely have a far greater impact on preventing and reversing cardiometabolic morbidities and mortalities than lowering borderline cortisol secretion rates. Large randomized prospective trials of treatment of ACS are required to answer many of the above questions.

The natural history of “untreated” ACS. A recent New Zealand study, prospectively evaluated 101 patients with benign adrenal adenomas over a 3-year follow-up period. Nine patients had evidence of ACS at diagnosis (defined as an elevated 24-hour UFC and a low DST), while the remaining 92 patients were diagnosed with a nonfunctioning AI. At 3 years, 5 of the 9 patients with ACS at diagnosis (44%) showed normalization with a nonfunctioning AI. Of the 92 patients with a nonfunctioning AI, 5 of the 92 patients with a diagnosis of ACS at diagnosis (5%) developed ACS at 3 years, 5 of the 92 patients with a nonfunctioning AI had evidence of ACS at diagnosis (5%).

Table 7. Summary of published studies evaluating the effect of adrenalectomy on clinical and biochemical features of autonomous cortisol secretion.

| Study, year (ref.) | Design | Diagnostic criteria DST cortisol nmol/L ACTH pg/mL | Operated patients (n) | Arterial HTN | Weight | Impaired glucose metabolism |
|--------------------|--------|-----------------------------------------------|---------------------|--------------|--------|-----------------------------|
| Perysinakis 2013 (250) | Retrospective no control | DST >50 and 1 of the following ACTH < 22 24-h UFC > 276 blunted diurnal CCR | 29 | 12/17 | 6/14 | 5/12 |
| Iacobone 2012 (251) | Retrospective | DST >138 ACTH < 22 high 24-h UFC | 20 | 8/15 | 6/15 | 5/10 |
| Maehana 2012 (252) | Retrospective nonfunctioning No control | DST >50 and 1 of the following: low ACTH, loss of CCR, scintigraphy, low DHEAS | 13 | 5/7 | n/a | 2/2 |
| Guerrieri 2010 (253) | Retrospective | 2 of the following: DST >50, high 24-h UFC ACTH < 22 | 19 | 12/12 | n/a | n/a |
| Chiodini 2010 (254) | Retrospective | 2 of: the following DST > 83, high 24-h UFC, ACTH < 22. | 25 | n/a | n/a | n/a |
| Toniato 2009 (255) | Prospective randomized | DST > 69 and 2 of the following: low ACTH, high 24-h UFC, loss of CCR, low DHEAS | 23 | 12/18 | 3/6 | 5/8 |
| Tsuiki 2008 (243) | Retrospective | DST (8mg) >28 and one of the following: ACTH < 22, blunted ACTH after CRH, loss of CCR, low DHEAS, scintigraphy | 10 | 5/6 | 0/3 | 2/9 |
| Salcuni 2016 (256) | Retrospective controls refused surgery | DST > 138 or 2 of the following: DST > 83 low ACTH high 24-h UFC | 32 | No change | — | No change |

Adapted from Iacobone et al. (257).
Abbreviations: n/a, not assessed/available; DST, dexamethasone suppression test; ACTH, adrenocorticotropic hormone; UFC, urinary free cortisol; CCR, cortisol circadian rhythm (ratio of plasma cortisol at 24.00 hours to 08.00 hours > 50%); DHEAS, dehydroepiandrosterone sulfate; CRH, corticotropin-releasing hormone.
Barzon et al. reported the cumulative incidence of ACS after 1 and 5 years as 3.8% and 6.6%, respectively (68). An Italian group reported an increased risk of ACS development if the adenoma size was >2.4 cm (sensitivity 73.3% and specificity 60.5%, P = 0.014) (244).

A recent systematic review and meta-analysis reported the follow-up of 4121 patients with nonfunctioning adrenal tumors (NFATs) and/or mild autonomous cortisol excess (MACE) (269). Clinically overt hormone excess (Cushing’s syndrome) was unlikely to develop (<0.1%) in patients with NFATs or MACE. Only 4.3% of patients with NFATs developed MACE, and pre-existing MACE was unlikely to resolve (<0.1%). Hypertension, obesity, dyslipidemia, and type 2 diabetes were more likely to develop and worsen in MACE than NFATs and new cardiovascular events were more prevalent in MACE (15.5%) than NFATs (6.4%) during follow-up. However, reported mortality (11.2%) was similar between NFATs and MACE.

Guidelines suggest that where functional secretion has been excluded at diagnosis, repeat endocrine testing is not required unless clinical features significantly change (4). Annual clinical assessment for up to 5 years is recommended in patients with ACS (4) together with an ongoing individualized risk assessment for potential benefit from surgical intervention based upon strengthening evidence linking cortisol excess to clinical symptoms and signs.

**Screening for primary aldosteronism**

The discovery of hyperaldosteronism in the context of an AI is relatively uncommon, compared with the detection of cortisol hyperscretion or pheochromocytoma (45,270). Normokalemic primary aldosteronism (PA) has been reported in up to 5.5% of AI (271). A few publications have reported normotensive PA in AI; however, most of these patients demonstrated occasional hypokalemia (8,272-274). Hypertension and hypokalemia are the major classical clinical findings of PA and the presence of either in the context of AI should prompt appropriate screening investigations. PA is associated with low plasma renin activity (or concentration) because aldosterone-induced hypervolemia results in suppression of renin release (275). Although hypokalemia in the context of hypertension in a patient with AI is suspicious of PA, the finding of hypokalemia is not a reliable marker. A recent multicenter analysis estimated that only 9% to 37% of patients with primary hyperaldosteronism were hypokalemic (276,277).

PA is associated with an increased risk of stroke (odds ratio [OR] 2.58, 95% CI 1.93-3.45), coronary artery disease (1.77, 1.10-2.83), atrial fibrillation (3.52, 2.06-5.99), heart failure (2.05, 1.11-3.78), and mortality (hazard ratio [HR] 1.34, 95% CI 1.06-1.71) compared with matched populations with essential hypertension (278,279). Therefore, the diagnosis of PA is important and requires either surgical excision or targeted antihypertensive therapy with mineralocorticoid receptor antagonists. Diabetes mellitus/metabolic syndrome (278,279), renal damage (280), impaired bone mineral density (81), and osteoporosis (264,281,282) have also been reported to be more prevalent in AI patients with PA.

Clinical guidelines recommend screening for PA in every (AI) patient with hypertension or hypokalemia (283,284). However, normotensive patients with supressible aldosterone/renin ratios may frequently develop hypertension and PA (285). Brown and colleagues (285) reported that populations with suppressed plasma renin activity (≤0.5 ng/mL/h) and high aldosterone levels were at increased risk of hypertension (HR 1.18; 95% CI 1.03-1.36) (285). These studies draw attention to the concept of a pre-clinical stage of PA. Further studies are required before the routine screening of all AI patients is recommended.

The 3-step approach for screening, confirmatory, and subtype classification of PA has been thoroughly covered in an excellent Endocrine Society Clinical Practice Guideline and will not be repeated here (284). Only to say that initial assessment using plasma aldosterone concentrations and plasma renin activity or the direct renin concentration and derivation of the aldosterone/renin ratios yields a sensitivity of 68% to 94% and negative predictive value approaching 100%.

**AI-secreting sex steroids**

AIs that secrete either estrogen or testosterone in isolation are rare. Although benign cortisol-secreting adenomas may very rarely produce androgens (286), elevated sex steroids are highly suspicious for ACC and urgent diagnostic evaluation is required (287-289).

In women, androgen-secreting tumors may present with features of virilization, such as excessive facial hair growth, skin changes such as acne, deepening of the voice, clitoromegaly, and male pattern baldness. Estrogen-secreting tumors in women may cause irregular uterine bleeding and breast tenderness. In men, estrogen-secreting tumors may cause feminization with decreased libido, testicular atrophy, and gynecomastia as key clinical features.
Multiple different groups have developed guidelines for the work-up of AIs (4). A key consideration for the diagnostic workup of an AI is whether there is a possibility of malignancy. Patients with an AI >1 cm in the short axis should undergo an imaging procedure to determine if the lesion is benign or malignant at the time of initial diagnosis. Some lesions with overtly benign features such as the presence of bulk macroscopic fat (myelolipoma) or simple cysts may not require any further imaging assessment.

Multiple imaging parameters are employed for the differential diagnosis of AI. There is a correlation between tumor size and risk of adrenocortical cancer: 2% risk in AIs <4 cm, 6% in AIs 4.1 to 6 cm, and 25% in AIs >6 cm (290). A large Italian study of patients with AI (n = 887) reported that 90% of ACCs had a diameter of >4 cm at presentation, a 4-cm cut-off had a 93% sensitivity for detecting ACCs (64, 137). Other imaging features used for characterization include unenhanced CT with the assessment of tumor density, contrast-enhanced timed washout CT studies, MRI chemical shift analysis, and, more recently, 18-fluorodeoxyglucose (FDG) positron emission tomography (FDG-PET) in combination with CT (PET-CT) (291).

Unenhanced CT
For all AIs, a noncontrast (unenhanced) CT is recommended as the first-line investigation. HU assessment on an unenhanced CT is a method for quantifying X-ray absorption of tissues compared with water, which conventionally has a HU of 0 (Fig. 6). Care is required when placing a region of interest to measure HU, this should cover at least two-thirds of the circumference of the nodule while avoiding areas of heterogeneity such as necrosis or calcification (292,293). A recent meta-analysis (291) on the use of imaging for differentiating benign from malignant adrenal lesions identified only 2 studies with 102 true incidentalomas, based on strict meta-analysis inclusion criteria. In patients without known extra-adrenal malignancy, an HU of ≤10 on a noncontrast CT is consistent with a lipid-rich benign adenoma (294). Importantly, the assessment of HU is for homogeneous lesions and care must be taken in heterogeneous lesions given the variability of HU and the potential to miss more solid components that may be malignant.

Contrast-enhanced washout CT
Approximately 30% of benign adrenal adenomas do not contain large amounts of fat and have an attenuation value of >10 HU (ie, lipid-poor adenomas), these lesions cannot be reliably characterized on unenhanced CT due to an overlapping density with malignant lesions and pheochromocytomas (295,296). For lesions with an attenuation value of >10 HU, further assessment is required and there is no clear consensus regarding which is the best second-line imaging for these patients. Our institutional practice is to perform a dedicated adrenal washout protocol CT as the next test because this is more accurate for characterizing lipid-poor adenomas than MRI (297), although as a recent meta-analysis has shown there is a need for further studies to

Figure 6. Characterization of AI by CT. Axial images obtained pre and post-IV contrast at the portal-venous (60-70 seconds) and delayed (10-15 minutes) phases post-injection. Calculation of adrenal lesion attenuation value showing benign pattern washout in a lipid-rich left adrenal adenoma.
optimize this technique as there is significant variability in scanning protocols and timings described and sensitivities and specificities (291).

Washout studies consist of CT imaging performed before and at 2 time points after administration of intravenous contrast (typically, imaging is performed at 60-90 seconds and 10 or 15 minutes postcontrast) with no clear evidence about the best time interval for the later time point (298). Adenomas typically enhance rapidly and show prompt washout of intravenous contrast, in contrast to malignant adrenal lesions which usually enhance rapidly but demonstrate a slower washout of contrast medium. Absolute washout values of >60% (early enhanced HU – delayed HU)/(early enhanced HU – unenhanced HU) × 100% suggest a benign adenoma (295,299). Relative washout can be calculated when unenhanced CT is not available (early enhanced HU – delayed HU)/enhanced HU × 100%. Values of > 40% suggest a benign adenoma (296,299,300) (Fig. 6). However, only 1 previous study has evaluated the test performance of CT contrast-enhanced washout in the evaluation of truly incidentally discovered adrenal masses (301), that is in patients not undergoing surveillance imaging for previous nonadrenal malignancy. This study reported high sensitivity (96%) and specificity (95%) for differentiating benign from malignant adrenal lesions (301); however, it considered only 50 cases, therefore larger prospective studies are required to validate the performance of contrast CT washout in patients with AI. Caution is also required because whilst pheochromocytomas usually show slow contrast washout, occasionally they can mimic benign lipid-poor adenomas by showing rapid washout (302). Therefore, following multidisciplinary team (MDT) discussion if there is still a suspicion regarding a lesion with indeterminate HU further scanning should be requested to ensure no further growth.

**Dual-energy CT**

Dual- or multi-energy CT is becoming more widely available and can provide additional specific data about attenuation properties of different materials at different energies (303). A frequent clinical dilemma is the detection of an AI on a single-phase contrast-enhanced CT typically performed 60 to 90 seconds postcontrast administration when the HU value of benign adenomas and nonadenoma lesions overlap significantly (304). Dual-energy CT offers the potential to extract a virtual noncontrast CT dataset from routinely acquired variable energy single-phase contrast-enhanced CT (305). A recent systematic review and meta-analysis reported that virtual non-contrast CT images generated from dual-energy CT demonstrate comparable sensitivity with standard noncontrast CT for diagnosis of lipid-rich adenomas, but data were only available from a small number of heterogeneous studies at high risk of bias (306). This technique requires prospective evaluation in a larger patient cohort before routine clinical use.

**Magnetic resonance imaging**

More recent guidelines suggest that MRI evaluation of adrenal lesions should be used primarily as a problem-solving tool. MRI with chemical shift imaging should only be the first choice where CT is less desirable, for example during pregnancy, in children, or for patients with allergies to iodinated contrast (this is not an issue in noncontrast scans) (307). The use of chemical shift MRI to detect intracellular fat within lipid-rich adrenal adenomas and differentiate these from other lesions was first described in 1992 (310) (Fig. 7). There are both qualitative (visual analysis) and quantitative methods of imaging evaluation which involve assessing change in signal intensity of adrenal lesions between in-phase and out-of-phase sequences (309). A recent systematic review and meta-analysis reported that visual analysis and quantitative analysis of adrenal signal intensity index and adrenal-to-spleen ratio all have high accuracy for lipid-rich adenoma detection (95-98%), and diagnostic performance is not significantly improved by adrenal signal intensity index or the adrenal-to-spleen ratio (310). Consequently, if AIs are detected on MRI and findings are unambiguous for a benign lipid-rich adenoma further imaging may not be warranted.

**Positron emission tomography-computed tomography**

FDG PET-CT has high diagnostic accuracy for characterization of adrenal masses with a pooled sensitivity of 91% and specificity of 91% in a recent meta-analysis of 29 studies involving 2421 patients (311). This technique is more expensive and less available than CT and MRI but may help to discriminate metastatic disease from benign masses in patients with known malignancy (4,312) (Fig. 8). One limitation is that benign adrenal lesions particularly functional adenomas and nonmetastatic pheochromocytomas can be FDG positive (313,314). As with MRI, there are both qualitative (visual analysis) and quantitative criteria used for the diagnosis of malignant adrenal lesions. Visual assessment of FDG activity within adrenal lesions compared to background
(physiological) uptake in the liver or blood pool has similar pooled sensitivity and specificity (91-92%) to quantitative analysis using adrenal to liver standardized uptake value (SUV) ratio (89-91%) or maximum SUV (SUV\textsubscript{max}) (85-91%) (309). False-negative findings are recognized in the setting of small malignant lesions, metastases from non-FDG avid tumors such as some subtypes of renal carcinoma and well-differentiated neuroendocrine malignancies and in necrotic lesions (315).

In patients with a suspected solitary adrenal metastasis being considered for adrenalectomy, FDG PET-CT should be considered to exclude extra-adrenal metastatic disease not detected on CT or MRI (4). 

**Follow-up imaging**

European guidelines suggest no further imaging for patients with adrenal lesions with benign characteristics <4 cm in diameter (4). This is further
supported by a recent systematic review and meta-analysis of nonfunctioning adrenal lesions where a mean tumor growth of 2 mm occurred over a median of 52.8 months, and clinically significant tumor enlargement (≥10 mm) occurred in only 2.5% of patients, and none developed adrenal cancer (269).

Data from a large Italian cohort study reported a 4 cm size cut-off had the highest sensitivity (93%) but low specificity (24%) for prediction of malignancy (66). For this reason, larger lesions with clear benign features warrant interval reassessment with imaging after 6 to 12 months to exclude significant growth (>20% increase in size with at least 5 mm absolute increase in diameter) which would prompt surgical resection. Less marked interim lesion growth warrants reassessment with a further scan after 6 to 12 months.

Ideally, every patient with an AI should be managed by an expert MDT; incorporating an endocrinologist, radiologist, pathologist, and a surgeon, with significant expertise in adrenal tumors. However, this is a challenging aspiration given the increasing prevalence of AI. Therefore the ESE/ENSAT guideline (4) identifies certain patients who are most likely to benefit from MDT discussion. This includes conditions where one of the following criteria is met; imaging is not consistent with a benign lesion; there is evidence of hormone excess (including ACS); there is evidence of significant tumor growth during follow-up imaging; and where adrenal surgery is considered.

Special Circumstances

Bilateral adrenal incidentalomas

Bilateral adrenal masses may represent co-occurrence of different entities; therefore both lesions should be separately assessed as per recommendations for a unilateral lesion (4). Interestingly, in patients with bilateral disease, it is possible for 1 mass to be a nonfunctioning cortical adenoma while the other mass may be hormone secreting (316). Additionally, there is a possibility that both masses (particularly in the context of hemorrhage and metastases) may lead to adrenal hypofunction and therefore this should be considered in the evaluation of the patient with bilateral AIs.

Bilateral AI and ACS. ACS is more frequently encountered in patients with bilateral AI than in those with unilateral lesions (317-319). A prospective study of 298 patients (224 with unilateral AI and 74 with bilateral AI) reported evidence of ACS in 35.1% of patients with bilateral AI, but only 17.9% of patients with unilateral AI (P = .003) (319). This supports previous retrospective studies (320-322) and a more recent surgical series including 112 unilateral AI and 23 bilateral AI, where mild cortisol excess was present in 21.7% bilateral AI versus 6.2% of unilateral AI (321). Vassiliadi et al. (320) demonstrated an exaggerated response of cortisol and ACTH in patients with bilateral AI during the combined tests of a DST followed by CRH stimulation when compared with unilateral AI and to a control group suggesting that regulation of the hypothalamic–pituitary axis was disturbed in patients with bilateral AI; however the diagnosis of BMAH was not excluded in this group (319).

PBMAH is suspected when there are bilateral AI and evidence of ACS (323). Cortisol secretion is in part regulated by the expression of multiple aberrant G protein-coupled receptors in the zona fasciculata cells including receptors for vasopressin, serotonin, luteinizing hormone/human chorionic gonadotropin, β -adrenergic agonists, gastric inhibitory polypeptide, glucagon, and angiotensin (324). These G protein-coupled receptors lead to activation of cAMP–PKA signaling pathway, similar to the pathway activated by ACTH receptor consequently leading to the transcription of steroidogenic factors.

On unenhanced CT, both adrenal glands are enlarged usually with multiple nodules but diffuse enlargement without nodules is also seen (325). On contrast-enhanced imaging, nodules can have marked enhancement, and HU >10 has also been described. Despite PBMAH being a benign disease limited studies using FDG uptake demonstrated an uptake similar to that seen in malignant tumors (326).

Bilateral AI and CAH. CAH can rarely present as bilateral adrenal lesions in adult life, although the majority of patients present with symptoms of adrenal insufficiency in childhood. The most common form of CAH, affecting over 90% of individuals, involves the gene for 21-hydroxylase and if suspected 17-hydroxyprogesterone (17-OHP) testing and mutation analysis for the gene CYP21B should be undertaken. The measurement of 17-OHP in the setting of bilateral adrenal hyperplasia should be interpreted with caution. In some cases, increased levels of 17-OHP may represent increased secretion of steroid precursors (327) from the lesion(s) especially in malignant tumors or in bilateral macronodular adrenal hyperplasia.
In these cases, low or suppressed ACTH levels may argue against CAH.

**Bilateral AI and pheochromocytoma.** Pheochromocytomas occur bilaterally in 10% cases and although some cases are sporadic, they are often seen as part of a genetic syndrome, discussed in detail in “Etiology: Tumors of the Adrenal Medulla.” It should be noted that patients who have a unilateral pheochromocytoma may also have an incidental adrenal adenoma and as such every adrenal lesion should be assessed individually.

**Bilateral AI and metastases.** The most common primary cancers to metastasize to the adrenal gland include lung, breast, renal, melanoma, and the gastrointestinal tract, although multiple other primary sites have been reported. The adrenal glands have been reported to be the fourth most common site of metastases in malignancy. In up to 75% of patients with an AI and extra-adrenal cancer, the adrenal mass is a metastasis and bilateral adrenal metastases are seen in a significant number of patients. However, 25% of patients with extra-adrenal cancer will have a primary adrenal lesion (101).

From an endocrine perspective, bilateral adrenal metastases may rarely cause adrenal insufficiency and patients should be clinically assessed and undergo further investigations if suspected. A unilateral adrenal metastasis would not cause adrenal insufficiency and patients do not usually require evaluation.

**Management of bilateral AI.** Surgical management of unilateral AI is discussed in “Surgical Management of Adrenal Incidentaloma.” The management of bilateral AI is challenging because the size of the tumor is not a criterion for surgery. As there is no clear consensus on the criteria defining abnormal cortisol secretion, the indication for adrenalectomy in the case of bilateral adrenal lesions remains controversial. Bilateral adrenalectomy may be considered if urinary cortisol levels are higher than 3 to 4 times the upper limit of normal with both adrenals having a relatively symmetrical size (324). The European Society of Endocrinology suggests that in selected patients, unilateral adrenalectomy of the dominant lesion may be considered based on the age of the patient, degree of cortisol excess, general condition, comorbidities, and patient preference (4). A recently published observational study analyzed the long-term clinical and biochemical outcomes of unilateral adrenalectomy versus bilateral adrenalectomy in patients with PBMAH and ACS and compared it to the outcome of cortisol-producing adenomas treated with unilateral adrenalectomy (328). The data, albeit retrospective and observational, showed that unilateral adrenalectomy of patients with PMAH lead to initial clinical remission in 84% of patients but at follow-up (median, 50 months), only 32% of patients were biochemically controlled (defined as a cortisol after dexamethasone <1.8 μg/dL) compared with all patients with bilateral adrenalectomy and unilateral adrenalectomy for a cortisol-producing adenoma. Additionally, 3 deaths occurred in the group of patients who were not biochemically controlled after unilateral adrenalectomy.

Bilateral adrenalectomy is recommended for bilateral pheochromocytomas; however, the risk of adrenal insufficiency and the side effects of lifelong glucocorticoid replacement have led to certain centers performing adrenal cortex sparing resections particularly in the setting of genetic syndromes such as VHL and MEN2A where the risk of malignant tumors is low (325).

**Adrenal gland biopsy**

The number of adrenal biopsies has significantly reduced in recent years due to improvements in noninvasive imaging techniques, which can increasingly accurately diagnose benign adrenal lesions. There are a number of reasons not to perform a biopsy on an adrenal lesion which includes the risk of seeding of adrenal cancer after biopsy (329), the adverse hemodynamic effects of performing a biopsy on an undiagnosed pheochromocytoma or paraganglioma, and most importantly of all it is frequently not possible to distinguish between an adrenal adenoma and an adrenal cortical carcinoma on the sample which is obtained and therefore it often does not help the clinical decision-making process.

In a recent systematic review and meta-analysis, Bancos et al. concluded that an adrenal biopsy is most useful in confirming the diagnosis of metastasis from extra-adrenal cancer (330). It should only be undertaken following detailed discussion at an adrenal tumor multidisciplinary meeting and if the lesion is not conclusively benign on imaging and, most importantly, the outcome will affect the therapeutic management of the patient (eg, if the patient has an extra-adrenal primary and a lesion in the adrenal would affect the staging and further management of the patient). Pheochromocytoma should be excluded before an adrenal biopsy, to prevent precipitating a potential hypertensive crisis. The biopsy itself is not without risk. The
most frequent complications are pneumothorax (due to the proximity of the adrenal gland to the diaphragm) and hemorrhage. Patients should, therefore, be able to hold their breath and have normal coagulation (331).

**Surgical Management of Adrenal Incidentaloma**

**Indications for unilateral adrenalectomy**
The principle threat of a unilateral adrenal lesion, with indeterminate imaging characteristics, is an ACC. For ACC without metastases, surgery is the most important single therapeutic measure. Guidelines recommend that surgery for patients with ACC should be limited to referral centers and performed by surgeons with expertise in adrenal surgery (open and laparoscopic) and with a volume of more than 15 adrenalectomies per year (benign and malignant) (332).

Patients with a functional unilateral adenoma, with clinically significant hormone excess, are offered unilateral adrenalectomy. Patients with a unilateral adrenal adenoma and ACS, are considered for surgery on an individual basis and after MDT discussion (4). Surgery is taken into consideration along with the patient's age, degree of cortisol excess, general health, comorbidities, and patient preference. In all patients, considered for surgery, ACTH-independent cortisol excess should be confirmed (4).

There is no absolute size for the recommendation of surgery in nonfunctioning adenomas. Due to the paucity of follow-up data on the natural history of large suspected benign AIs, and the realization that the larger the mass, the higher the incidence of malignancy (333), surgery may be considered in larger lesions (>4 cm) even if imaging characteristics suggest a benign lesion. Any indeterminate nodule on imaging greater than 4 cm should be offered surgery (4).

Occasionally myelolipomas and adrenal cysts are removed if they get to a significant size and cause compressive symptoms. Adrenal metastases are resected if appropriate in the context of the underlying pathology. In general, patients are deemed suitable if the underlying extra-adrenal malignancy is controlled, the metastasis is isolated to the adrenal gland and the patient has an adequate performance status to justify aggressive treatment.

**Perioperative care of patients for adrenalectomy**
Adrenal surgery involves a multidisciplinary team approach in order to achieve the best outcomes. Any patient who has unilateral adrenalectomy for Cushing’s syndrome or evidence of ACS is at risk of contralateral adrenal gland suppression, due to the chronically elevated pre-operative cortisol levels with consequent ACTH suppression and adrenal atrophy. Peri- and postoperative stress dose glucocorticoids are required, which are weaned down to oral maintenance therapy prior to discharge. After unilateral adrenalectomy, patients require regular follow-up and synacthen testing to assess when the contralateral adrenal function recovers and steroid replacement can be stopped. All patients require education regarding hydrocortisone treatment prior to discharge and an understanding of adrenal insufficiency sick rules.

Before adrenal surgery for pheochromocytoma patients are treated with α -blockers, intra-vascular volume expansion, and in some patients β -blockers (particularly if concerns regarding tachyarrhythmia are present) (180). After the tumor is devascularized, especially after dividing the adrenal vein intraoperatively, patients may develop profound hypotension, which requires fluid optimization and inotropic support, which may need to be continued in the initial postoperative period (334).

Patients with AI and primary hyperaldosteronism are often prescribed a mineralocorticoid receptor antagonist, such as spironolactone or eplerenone. Following adrenalectomy for PA, this should be discontinued to prevent hyperkalemia. Other antihypertensives are stopped or reduced depending on the patient's postoperative blood pressure. Older patients and those with longstanding hypertension are more likely to have irreversible vascular damage and have persistent hypertension requiring antihypertensive medication, despite successful surgery (335).

**Surgical techniques**
Adrenal surgery has significantly changed over the past 100 years. There have been multiple open approaches to the adrenal gland, including transperitoneal, posterior, and flank. In 1992 the first laparoscopic transperitoneal adrenalectomy was performed and more recently the laparoscopic posterior (retroperitoneoscopic) adrenalectomy technique has been developed.

Laparoscopic adrenalectomy is now considered the gold standard of surgical treatment for the majority of small and medium-sized adrenal lesions. Multiple studies have demonstrated a shorter hospital stay, reduced pain, minimal morbidity, and improved recovery (336). The adrenal is a relatively inaccessible organ and difficult to access through an open incision, therefore lending
itself to minimally invasive surgery. The posterior retroperitoneoscopic adrenalectomy has been developed more recently and uses high insufflation pressures in the retroperitoneal cavity. It provides direct access to the adrenal gland, avoids the intraperitoneal cavity and allows bilateral procedures to take place without repositioning the patient. Disadvantages of the posterior retroperitoneoscopic approach include a smaller working space, which makes removal of larger tumors more challenging and increased difficulty in patients with a high body mass index (BMI). This technique has been reported to lead to reduced post-operative analgesia and length of hospital stay (337,338).

More recently robotic-assisted laparoscopic adrenalectomy has been developed via the transperitoneal technique and has been shown to be safe and effective. Robotic surgery offers a greater range of motion, improved magnification, and stereoscopic vision than traditional laparoscopic surgery. The main advantages have been reported in patients with a high BMI and larger tumors. However, there is an increased cost, longer operative time, and a significant learning curve (339).

The role of laparoscopic surgery for the treatment of ACCs remains controversial. Complete resection (R0) of the entire tumor along with any adjacent involved structures or lymph nodes is the only chance of cure. Laparoscopic surgery is only advised if the tumor can be removed completely with an intact adrenal capsule and there is no evidence of tumor invasion. Based on the available data and clinical experience, the European guidelines suggest that laparoscopic adrenalectomy may be justified for adrenal tumors ≤6 cm with radiological signs of malignancy and without evidence of local invasion (4). Open resection is recommended in larger tumors due to the higher risk of tumor capsule rupture and in those with any evidence of local invasion and or when adjacent organ resection is required. The decision to convert to an open procedure should be made early, before any rupture of the tumor capsule (340). In many cases, an individualized decision process by a multidisciplinary team is required to find the best surgical approach for a given patient.

Solitary adrenal metastases often are confined within the adrenal gland and laparoscopic adrenalectomy is a safe technique, which achieves negative margins and reduces patient morbidity (340). If there is any evidence of local invasion into surrounding tissue intraoperatively the procedure should be converted to an open operation.

**Follow-up in patients without surgery**

The American Association of Clinical Endocrinologists recommends repeated imaging for up to 5 years for benign tumors (86). However, the more recent European guidelines do not recommend further imaging for benign, nonfunctioning lesions of less than 4 cm (4). Patients with adrenal lesions over 4 cm or indeterminate lesions, who have not undergone surgery are recommended to have repeat imaging, either a noncontrast CT or MRI in 6 to 12 months, the optimal timing is at the discretion of the MDT and depends on the index of suspicion (4). Surgical resection is recommended if there is a 20% increase in size, in addition to at least a 5 mm increase in diameter over this period. Both adrenocortical cancers and metastases usually demonstrate rapid growth over months, in contrast to a benign adenoma. Further imaging should be undertaken, again at 6 to 12 months, if there is an increase in size, but not at the threshold for surgical intervention (4). For younger patients, MRI surveillance, rather than CT, is preferred due to lower radiation exposure. In elderly patients follow up with imaging, even with nodules over 4 cm might be favored over surgery, in the presence of multiple comorbidities. Patients are treated on an individual basis but it is acknowledged that many clinicians and patients would not feel comfortable following up a tumor over 4 cm on imaging, even if radiologically benign, in a young patient and surgery is often the preferred option.

Repeat hormonal testing is not advised in patients without evidence of hormone oversecretion on their initial assessment (4). It should only be considered if patients develop new clinical signs of adrenal hormone hypersecretion or worsening of comorbidities, including diabetes, hypertension, or osteoporosis (4).

The risk of patients with ACS progressing to overt Cushing’s syndrome is negligible; however, ACS is associated with numerous comorbidities (269). If patients with ACS do not undergo surgery initially, they should be annually reassessed for cortisol hypersecretion and potential worsening of comorbidities. If there is clinical or biochemical progression then patients can be re-evaluated for surgery (341).

**The Future: Investigation and Management**

Given the sensitivity and specificity limitations of standard endocrine testing (discussed in “Endocrine Work-up of AI”) and radiological investigations (discussed in “Imaging Evaluation
of an AI”) in determining whether an adrenal lesion is benign or malignant, further advances are required to help risk-stratify patients with adrenal lesions.

The role of urine steroid metabolomics
Standard serum steroid measurements are variable because of the diurnal variation in adrenal steroid secretion. Twenty-four-hour urine steroid excretion analysis represents a more accurate estimate of total corticosteroid production and of adrenal precursor steroids and metabolites (342, 343) and therefore has significant potential in the assessment of adrenal diseases. This has been extensively reviewed by Storbeck et al. (344).

Adrenal steroid production and metabolism are affected by sex, age, and BMI (342,345,346). Glucocorticoid metabolites are higher in men than in women and in obese than in lean persons (345,346). Assessing ratios of steroids that are substrates and products, respectively, of a distinct steroidogenic enzyme activity allows for representative assessment of elements of the steroidogenic pathway, which has been particularly informative in the diagnosis of inborn steroidogenic disorders, including CAH.

Mass spectrometry. There are a number of different methods of mass spectrometry including gas chromatography-mass spectrometry (GC-MS) and LC-MS/MS (191,220,327), each of which has its pros and cons, which have been reviewed in detail by Krone et al. (347). In mass spectrometry, steroids are identified by unique retention times and or multiple reaction monitoring (206) with the area under the peak in the chromatogram is proportional to its concentration and quantifiable via comparison to standard reference materials of known concentration.

Urinary steroid profiling using GC-MS permits the analysis of multiple corticosteroids and their metabolites from a single urine sample (347) (Fig. 9). As most urinary steroids are conjugated, samples need to be deconjugated followed by a derivatization step before analysis which is both time consuming and labor intensive. LC-MS/MS is considerably faster and less labor intensive and allows a much higher throughput than GC-MS; however, LC-MS/MS has a poorer resolving capacity (206). As a result, LC-MS/MS is more suited to a smaller panel of corticosteroids and their metabolites and as a result does not have the same broad scope of analysis that GC-MS allows (206).

Given the preanalytical and analytical advantages of LC-MS/MS over GC-MS, it is better suited to clinical practice once adequate optimization has been performed. However, GC-MS has several advantages, particularly in the research environment, over LC-MS/MS, including a better chromatographic resolution which permits the ready characterization of structures; use of GC-MS in scan mode allows for nontargeted steroid profiling and the discovery of novel compounds, metabolomes, and pathways of synthesis and metabolism. Importantly, scanned data can be stored indefinitely for future research (347).

Use of urinary steroid metabolome in research and clinical practice. Increasingly, the results from panels of multiple steroids are being analyzed using novel statistical technical techniques including machine learning (which allows for the discovery of diagnostic and disease-specific patterns) revealing a personalized “urinary steroid metabolome.” This approach has been used for some time for diagnosing inborn errors of steroidogenesis such as CAH but has recently been developed for the evaluation of functionality and malignant potential of patients with adrenal nodules (281).

Use of urinary corticosteroid metabolism markers in differentiating between benign and malignant adrenal lesions. This area has been extensively reviewed recently by Bancos et al. (342,348-350). Studies have shown that ACCs have a distinct pattern of urinary corticosteroids, characterized by an excess of precursor steroid metabolites (Fig. 10 (342)). In particular, the cosecretion of a distinct combination of glucocorticoid and androgen metabolites is emerging as a sensitive diagnostic tool for ACC (342,348,349).

The study by Arlt et al. (342) assessed the 24-hour urinary steroid metabolome using GC-MS in 102 patients with benign adrenal adenomas and 45 patients with ACC. They used generalized matrix learning vector quantization to identify the most discriminate steroids which differentiated between a benign adenoma and a malignant ACC. They reported that 27% of patients with ACC had no hormonal excess on routine biochemical testing. Urinary steroid profiling revealed distinct differences between adrenocortical adenomas and ACC patients (Fig. 10). ACC patients had a significantly higher excretion of androgen precursor metabolites, metabolites of active androgens, deoxycorticosterone, and glucocorticoid precursor metabolites were significantly higher in ACC, as was free cortisol.

ACC patients exhibited significantly increased excretion of metabolites derived from the
Figure 9. (A) Schematic representation of steroidogenesis depicting the major products of adrenocortical steroid synthesis, the mineralocorticoid aldosterone (dark green), and its precursors (light green), glucocorticoid precursors (yellow), the active glucocorticoid cortisol (orange) and its metabolite cortisone, and the adrenal androgens and their precursors (light blue). Synthesis of active androgens (dark blue) mainly takes place in the gonads. (B) The 24-hour urinary steroid metabolite excretion in healthy controls (n=88). Box plots represent median and interquartile ranges; the whiskers represent 5th and 95th percentile, respectively. Color coding of steroid metabolites mirrors that used for depicting the major adrenal corticosteroid classes in (A). CYP, cytochrome P450; HSD, hydroxysteroid dehydrogenase; DHT, 5α-dihydrotestosterone (342). From Arlt W, Biehl M, Taylor AE, Hahner S, Libe R, Hughes BA, Schneider P, Smith DJ, Steikema H, Krone N, Porfiri E, Opoche G, Berherat J, Mantero F, Alloio B, Terzolo M, Nightingale P, Shackleton CH, Bertagna X, Fassnacht M, Stewart PM. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011; 96:3775-3784 (Under Open Access License).
precursors of androgen, mineralocorticoid, and glucocorticoid synthesis. Even when analyzing the ACC patients without evidence of hormone excess on routine biochemistry, urinary excretion of androgen, and glucocorticoid precursor metabolites remained significantly increased. By contrast, steroid precursor metabolite excretion in nonmalignant AI did not differ from healthy controls. The majority of ACC patients (69%) showed androgen precursor excess, either combined with increased excretion of glucocorticoid precursors (36%) or both glucocorticoid and mineralocorticoid precursors (33%). There was no effect of age, sex, tumor size, or presence of metastasis on the characteristics of the urine steroid metabolomes in ACC and ACA patients. Using machine learning, the authors were able to identify that tetrahydro-11-deoxycortisol (THS), pregnenetriol (5-PT), and pregnenolone (5-PD) were the most discriminatory between ACC and ACA. They then included the next 6 most discriminatory to develop a panel that could be used for future validation on an LC/MS-MS platform (342).

Kotłowska et al. (343) have also reported the use of GC-MS analysis of 19 major urinary corticosteroids and their metabolites in 30 controls and 28 patients with “nonsecretory” incidentalomas. In this study, the diagnosis of an adrenal cancer was excluded by “examining the diameter of the tumor, its clinical image and properties revealed during additional test” and all adenomas were less than 4 cm as all lesions greater than this were surgically removed. Interestingly, 25% of patients with “nonsecretory” AIs had distinct patterns of urinary steroids compared to the controls and other patients with AIs. There is, therefore, the possibility that some of these patients could have had an autonomously secreting lesion or a small ACC.

In 2015, Kerkhofs et al. (348) reported data relating to 27 ACCs and 125 ACA patients. They performed GC-MS analysis of 22 steroid
metabolites and identified 15 individual steroid markers with a sensitivity of 90% or above in detecting ACC, with the 11-deoxycortisol metabolite (THS) again representing the most informative marker. Other informative markers identified by that study included pregnanediol, pregnanetriol, etiocholanolone, the major androgen metabolite androstenedione, and the major glucocorticoid metabolites tetrahydrocortisol and tetrahydrocortisone. In a recent study by Velikanova et al. (349), assessing 32 steroid metabolites by GC-MS in 24-hour urine samples from 31 patients with ACC and 96 patients with ACA, the authors confirmed the findings reported by Arlt et al. (342). Similar to Kerkhofs et al. (348) they did not employ unbiased computational data analysis of the steroid excretion data. All studies identified THS as the most informative steroid marker indicative of ACC. THS is the metabolite of 11-deoxycortisol, which is converted to cortisol by the adrenal-specific steroidogenic enzyme cytochrome P450 family 11 subfamily B member 1 (CYP11B1). Measurement of 11-deoxycortisol is not routinely used clinically, though recently serum results were reported in a cohort of benign adrenal tumors (249).

A recent study has also shown the utility of urinary steroid metabolomics in the follow up of patients with ACC as a marker of recurrence (351).

**Future directions and challenges with steroid metabolomics.** Arlt et al. have used GC-MS analysis to reveal previously unrecognized significant glucocorticoid excess in patients with primary hyperaldosteronism, labeled “Connshing” syndrome (281). They performed mass spectrometry-based analysis (GC-MS) of a 24-hour urine steroid metabolome in patients with primary aldosteronism in comparison to healthy controls, patients with endocrine inactive adrenal adenoma, patients with ACS, and with clinically overt adrenal cortisol excess. Patients with primary hyperaldosteronism had significantly increased cortisol and total glucocorticoid metabolite excretion. Several surrogate parameters of metabolic risk (including BMI, waist–hip ratio, fasting insulin, HOMA-IR, and high-density lipoprotein cholesterol) correlated significantly with glucocorticoid but not mineralocorticoid output.

Unilateral adrenalectomy resolved both mineralocorticoid and glucocorticoid excess, indeed, postoperative evidence of adrenal insufficiency as evidenced by a suboptimal cortisol response to synacthen testing was found in 29% of patients despite a normal preoperative dexamethasone suppression test.

These data are of significant interest given the other comorbidities reported in patients with primary hyperaldosteronism such as increased rates of insulin resistance/type 2 diabetes and osteoporosis, which were difficult to attribute to aldosterone effect per se (281). More research is needed in this area as it raises several important questions, not least the impact of this glucocorticoid excess in patients who are not surgically cured of their primary hyperaldosteronism but receive mineralocorticoid receptor antagonist therapy which has no antiglucocorticoid effect. Further prospective data are required to validate these retrospective studies.

There are several important future directions of research in this area including the potential to use a spot urine sample rather than a 24-hour collection and transferring this technology to an LC/MS-MS based high throughput platform which will be easily performed in routine biochemistry laboratories. In recent years, LC-MS/MS has also been used on serum samples to differentiate between benign and malignant adrenal disease (352,353).

Ultimately, the use of a noninvasive steroid metabolomic assessment may be able to risk-stratify patients rapidly and accurately, thus leading to prompt and appropriate therapy for patients with ACC and a reduction in the need for follow-up of patients with benign adrenal disease and unnecessary surgery for patients with radiologically indeterminate lesions. The combination of the above will hopefully lead to improved survival for patients with ACC as they are recognized and treated promptly and a decrease in healthcare costs (due to a reduction in surgical procedures) and exposure to ionizing radiation by reducing CT imaging in patients with benign disease (45).

**Other diagnostic innovations**

There are a number of other exciting developments in the field of adrenal tumors in terms of improved histopathological techniques that include In situ metabolomics utilizing high-mass resolution matrix-assisted laser desorption/ionization mass spectrometry imaging, which has been extensively reviewed by Papathomas et al. (206) and is beyond the scope of this review. Other advances include the use of molecular biology techniques to predict prognosis in patients with ACC (165,354-356) which may give the promise of delivering a more personalized approach to prognostication, treatment, and follow-up.

**Functional imaging of the adrenal cortex.**

Scintigraphy techniques have been used for...
imaging of the adrenal glands for several decades. Iodine-131 labelled 6-beta-iodomethyl-19-norcholesterol (NP-59), a cholesterol analog that incorporates into low-density lipoproteins and accumulates in the adrenal cortex via a receptor-mediated process, has been used for imaging of the adrenal cortex as a marker of adrenal cholesterol metabolism since the 1970s (357). The emergence of integrated single-photon emission computed tomography-computed tomography (SPECT-CT) systems has led to a resurgence of interest in the use of NP-59 scintigraphy (358). Recent data have reported a positive predictive value of 92% for differentiation of aldosterone-producing adenoma from bilateral adrenal hyperplasia in primary aldosteronism, potentially reducing the need for invasive adrenal venous sampling (359). Limitations of NP-59 scintigraphy including the requirement for prolonged dexamethasone suppression, the need for sequential imaging over several days, and relatively high radiation dose, have stimulated the development of other functional imaging techniques in the diagnosis of primary aldosteronism (360).

Etomidate derivatives with high affinity and specificity for enzymes within the cytochrome P450 11B family (CYP11B) which are expressed exclusively within adrenocortical cells have been developed (361). CYP11B1 (11-beta-hydroxylase) and CYP11B2 (aldosterone synthetase) enzymes are key regulators of adrenal cortisol and aldosterone synthesis (362). Carbon-11 (11C) metomidate (MTO) PET-CT is a sensitive and specific technique for diagnosing adrenocortical tumors (363) and has high accuracy for lateralizing aldosterone secretion by Conn’s adenomas (364,365). The 20-minute half-life of 11C restricts the use of this tracer to centers with an on-site cyclotron and consequently, this technique is not widely available (Fig. 11). This limitation has led to the development of longer half-life radiotracers which are required before more widespread availability can be achieved. Recently, an 18F-labeled analog of MTO (18F-FAMTO) has been developed with high selectivity for CYP11B enzymes (366). 123I-labeled iodometomidate (IMTO) has also been evaluated as a potentially more widely available radiotracer (367). 123I-IMTO SPECT-CT permits highly specific characterization of adrenocortical tissue with lower radiation exposure and investigation than NP-59 scintigraphy (368) and also has reported value for the staging of ACC (369). Labeling of metomidate with iodine-131 offers the potential for targeted radionuclide therapy in advanced adrenocortical cancer but this requires validation in a prospective clinical trial (370).

**Figure 11.** Carbon-11 metomidate PET-CT: Coronal PET maximum intensity projection and axial fused PET-CT images in a patient with a left adrenocortical carcinoma and an unsuspected tracer-avid right sided liver metastasis. Prominent physiological tracer uptake is present in the gastric wall and left renal collecting system. Images courtesy of Professor Anders Sundin, Consultant Radiologist, Uppsala University Hospital, Sweden.
Figure 12. Iodine-123 metaiodobenzylguanidine SPECT-CT. Anterior half-body planar view and axial fused SPECT-CT images in a patient with a large MIBG-avid right adrenal pheochromocytoma with an unsuspected tracer-avid bone metastasis within the manubrium.

Figure 13. Carbon-11 hydroxyephedrine PET-CT. Coronal PET maximum intensity projection and axial fused PET-CT images in a patient with a left adrenal pheochromocytoma and an unsuspected tracer-avid subcentimeter right paratracheal node which was biopsied and confirmed to represent a nodal metastasis. Images courtesy of Professor Anders Sundin, Consultant Radiologist, Uppsala University Hospital, Sweden.
Functional imaging of the adrenal medulla. Iodine-labelled metaiodobenzylguanidine (MIBG), a guanethidine analog, has been used for functional imaging of tumors arising from the adrenal medulla for over 30 years (371). 123I-MIBG has significant limitations, including a 2-day imaging protocol and the need for thyroid blockade with potassium iodide prior to tracer injection (Fig. 12). 124I-MIBG has been evaluated as a potential PET imaging tracer but this undergoes complex decay with emission of high energy gamma radiation leading to poorer image quality and unfavorable dosimetry (372). Other PET tracers including dopamine analogs such as 18F-fluorodopamine and 13F-fluorodihydroxyphenylalanine (DOPA) which image norepinephrine (noradrenaline) and amino acid transporter expression, along with 13C-hydroxyephedrine, a catecholamine analog, have been used to evaluate tumors arising from the neural crest (373) (Fig. 13). These tracers are limited to highly specialized centers and the published data is limited to relatively small cohorts. Recently an 18F-labeled analog of MIBG has been developed, meta-fluorobenzylguanidine (18F-MFBG); preliminary data report high accuracy and favorable dosimetry in a single-day protocol overcoming some of the limitations of other tracers and showing promise for the future (374).

Textural analysis/radiomics
Radiomics is a relatively new area of research activity which involves the extraction of “invisible”

**Figure 14.** CT textural analysis. Axial CT image showing left adrenal lesion segmentation (blue contours, top left) and adrenal lesion textural features displayed using fine (top right), medium (bottom left) and coarse (bottom right) filters using TexRADTM software. First-order textural parameters extracted from the lesion are tabulated below. SSF, spacial scaling factor; SD, standard deviation; MPP, mean of positive pixels.

| SSF | TX_sigma | mean  | sd   | entropy | mpp     | skewness | kurtosis |
|-----|----------|-------|------|---------|---------|----------|----------|
| 0   | 0        | 17.84 | 33.53| 4.65    | 35.18   | 0.18     | -0.4     |
| 2   | 1.05     | 18.81 | 86.95| 5.2     | 82.46   | 0.23     | -0.62    |
| 3   | 1.57     | 24.84 | 72.42| 5.06    | 67.23   | 0.34     | -0.06    |
| 4   | 2.09     | 26.04 | 51.22| 4.85    | 46.67   | 0.17     | 0.13     |
| 5   | 2.62     | 25.35 | 36.02| 4.63    | 39.51   | 0.12     | -0.32    |
| 6   | 3.14     | 22.66 | 28.39| 4.46    | 33.77   | 0.36     | -0.85    |
quantitative features from medical imaging based on intensity, shape, volume, and textural features (375). Textural analysis permits the evaluation of spatial inter-relationships within lesions to quantify lesion heterogeneity (376). The potential to obtain additional data from standard-of-care imaging could improve diagnostic accuracy and help guide optimal patient management (377) (Fig. 14).

Preliminary data on the use of CT textural analysis for the characterization of indeterminate adrenal lesions has shown promising results. In a feasibility study of 164 patients with indeterminate adrenal lesions at CT (98 pheochromocytoma; 66 lipid-poor adrenal adenomas), intraslide textural features (mean gray-level intensity and mean positive pixels) extracted from unenhanced images allowed differentiation between adenoma and pheochromocytoma with an accuracy of 81% (378). In a recent larger patient cohort (n = 225) the same Chinese group has reported an accuracy of 77% for distinguishing metastases from benign adrenal lesions using this CT textural feature analysis technique (379). Other groups have shown similar results in small retrospective series evaluating the accuracy of MRI and PET-CT textural features for distinguishing benign and malignant adrenal lesions (380,381).

### Machine learning and imaging

There is a great interest in the use of artificial intelligence and machine learning techniques in medical imaging (382). The combination of textural analysis with machine learning classification may improve diagnostic accuracy and reproducibility. Early data evaluating the efficacy of textural analysis-derived parameters extracted from MRI of adrenal lesions in 60 patients using a machine learning approach showed a diagnostic accuracy of 80% compared to expert radiologist accuracy of 73% (383). A feasibility study assessing machine learning-based quantitative textural analysis of unenhanced CT in 108 patients with indeterminate adrenal lesions had a 94% accuracy for differentiating pheochromocytoma from lipid-poor adenoma (384). At present, there is insufficient evidence to support clinical translation, but these techniques have the potential to improve diagnostic accuracy and more informed decision making in the future. These initial findings warrant validation in a well-designed prospective multicenter clinical trial.

### Conclusion

An AI is now established as a common endocrine diagnosis that requires a multidisciplinary approach for effective management. The majority of patients can be reassured and discharged, but a personalized approach based upon image analysis, endocrine workup, and clinical symptoms and signs is required in every case. ACC remains a real concern but is restricted to <2% of all cases. Functional AI lesions are uncommon (but still probably <10% of total) and the greatest challenge remains the diagnosis and optimum management of ACS. Modern-day surgery has improved outcomes and novel radiological and urinary biomarkers will improve early detection and patient stratification in future years to come.

### References

1. Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. JAMA. 2018;319(30):1024-1039.
2. Smith-Bindman R, Miglioretti DL, Johnson E, et al. Radiation exposure for patients enrolled in large integrated health care systems, 1996-2010. JAMA. 2012;307(22):2460-2469.
3. Operational Information for Commissioning NE Diagnostic Imaging Dataset Statistical Release: Provisional monthly statistics, November 2017 to November 2018. 2019. https://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2019/12/Annual-Statistical-Release-2018-19-PDF-1.9MB.pdf.
4. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas. European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34.
5. Greifenhagen GW, Druy EM. Management of the adrenal “incidentaloma.” Surgery. 1962;92(5):866-874.
6. Zeiger MA, Thompson GR, Duh QY, et al.; American Association of Clinical Endocrinologists; American Association of Endocrine Surgeons. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adren al incidentalomas. Endocr Pract. 2009;15(Suppl 1):1-20.
7. Tabarin A, Bardet S, Bertherat J, et al.; French Society of Endocrinology Consensus. Exploration and management of adrenal incidentalomas. French Society of Endocrinology Consensus. Ann Endocrinol (Paris). 2008;69(6):487-500.
8. Muth A, Hammarstedt L, Hellstrom M, et al. Swedish guidelines for the management of adrenal incidentalomas. Lancet. 2017;389:111.
9. Kokko JP, Brown TC, Berman MM. Adrenal adenoma and hypertension. Lancet. 1967;2(7488):468-470.
10. Hedeland H, Ostberg G, Hökfelt B. On the prevalence of adenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Med Scand. 1968;184(3):211-214.
11. Russell S, Blumenthal HT, Gray SH. Small adenomas of the adrenal cortex in hypertension and diabetes. Arch Intern Med (Chic). 1945;76(5):284-291.
12. Commons RR, Callaway CP. Adenomas of the adrenal cortex. Arch Intern Med (Chic). 1948;81(1):37-41.
13. Schroeder HA, Davies DF. Studies on “essential” hypertension. V. An endocrine hypertensive syndrome. Ann Intern Med. 1954;40(3):516-539.
14. Dévényi I. Possibility of normokalemic primary aldosteronism as reflected in the frequency of adrenal cortical adenomas. Clin Pathol. 1967;20(1):49-51.
15. Russell RP, Masu AT, Richter ED. Adrenal cortical adenomas and hypertension. A clinical pathologic analysis of 690 cases with matched controls and a review of the literature. Medicine (Baltimore). 1972;51(3):211-225.
16. Kawano M, Kodama T, Ito Y, Cibara T, Fujimoto Y. Adrenal incidentaloma—report of 14 operated cases and analysis of 4-year autopsy series of Japan. Nihon Geka Gaikan Zasshi. 1989;90(12):2031-2036.
17. Kobayashi S, Iwash H, Matsu O, Fukushima H, Ito Y, Masaoka A. Primary adrenocortical tumors...
in autopsy records—a survey of “Cumulative Reports in Japan” from 1973 to 1984. Jpn J Surg. 1991;21:494-498.

18. Rinnehart JF, Williams AO, Cappeller WS. Adenomatous hyperplasia of the adrenal cortex associated with essential hypertension. Arch Pathol. 1941;32:159-177.

19. Dempsey WS. The adrenal cortex in essential hypertension. Arch Pathol. 1942;34:1031-1034.

20. Dawson IM. Changes in the adrenal cortex in essential and renal hypertension. J Pathol Bacteriol. 1956;12:393-409.

21. Holmes RO, Moos HD, Rinnehart JF. A morphologic study of adrenal glands with correlations of body size and heart size. Am J Pathol. 1959;15:274-276.

22. Sharma AH, Goddard JW, Sommers SC. A study of the adrenal status in hypertension. J Chronic Dis. 1958;8(5):587-595.

23. Spirnak DM, Weinsaft P. Solitary adrenal cortical adenoma in elderly female, frequency. Arch Pathol. 1966;78:231-233.

24. Dobbe JW. Adrenocortical nodular hyperplasia: the ageing adrenal. J Pathol. 1969;99(1):1-18.

25. Yamada EY, Fukunaga FH. Adrenal adrenoma and hypertension. A study in the Japanese in Hawaii. Jpn Heart J. 1970;11:9-19.

26. Granger P, Genest J. Autopsy study of adenals in unselected normotensive and hypertensive patients. Can Med Assoc J. 1970;103(1):34-36.

27. Abecassis M, McLoughlin MJ, Langer B, Kudlow JE. Serendipitous adrenal masses: prevalence, significance, and management. Am J Surg. 1985;149(6):783-788.

28. Winkelmann M, Schoppe WD, Volk N, Bürgk RF, Jungblut RM, Schneider W. Correlation of abdominal CT imaging with autopsy findings in patients with malignant tumors. J Cancer Res Clin Oncol. 1987;113(3):279-284.

29. Meagher AP, Hugh TB, Casey JH, Chisholm DJ, Farrell JC, Yeates M. Primary adrenal tumours—a ten-year experience. Aust NZ J Surg. 1988;58(6):457-462.

30. Reinhard C, Saeger W, Schubert B. Adrenocortical nodules in post-mortem series. Development, functional significance, and differentiation from adrenomas. Gastroenterology. 1996;111(3):402-208.

31. Sington JD, Syn WK, Suvarna SK, et al. Lack of association between thyroid and adrenal nodules: a histological study. J Endocrinol Invest. 1999;22(2):262-265.

32. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993;328(17):1237-1243.

33. Glazer HS, Weyman PJ, Sagel SS, Levitt RG, McClellan BL. Nonfunctioning adrenal masses: incidental discovery on computed tomography. AJR Am J Roentgenol. 1982;139(1):81-85.

34. Prinz RA, Brooks MH, Churchill R, et al. Incidental asymptomatic adrenal masses detected by computed tomographic scanning. Is operation required? JAMA. 1982;248(6):701-704.

35. Belledgeun A, Hussain S, Selzter SE, Loughlin KR, Gittes RF, Richie JP. Incidentally discovered mass of the adrenal gland. Surg Gynecol Obstet. 1986;163(3):203-208.

36. Davenport E, Lang Ping Pang N, Wilson M, Red A, Aspinall S. Adrenal incidentalomas: management in British district general hospitals. Postgrad Med J. 2014;90(1065):365-369.

37. Maher DJ, Williams E, Grodzki S, Serpell JW, Lee JC. Adrenal incidentaloma follow-up is influenced by patient, radiologic, and medical provider factors: a review of 804 cases. Surgery. 2018;164(6):1360-1365.
aspects: single centre experience. Endocrine. 2010;37(1):40-46.
74. Anagnostis P, Efthatiadou Z, Polyzos SA, et al. Long term follow-up of patients with adrenal incidentalomas—a single centre experience and review of the literature. Exp Clin Endocrinol Diabetes. 2010;118(9):610-616.
75. Giordano R, Mannazzo E, Berardelli R, et al. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. J Endocrinol Invest. 2010;33(3):32-36.
76. Muth A, Hammerschled L, Hellström M, Sigurjónsdóttir HÁ, Almqvist E, Wängberg B; Group of Endocrine Abdominal Tumours. Adrenal incidentalomas. J Endocrinol Invest. 2010;33(4):202-206.
77. NakaMura Y, Yamazaki Y, Felizola S, et al. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathways. Endocrinol Metab Clin North Am. 2015;44(2):399-410.
78. Inoue K, Sasaki H, Yabuki N, et al. DNA topoisomerase II alpha and Kit-6 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol. 1997;10(9):901-907.
79. McNeil AM. Lesions of the adrenal cortex. Arch Pathol Lab Med. 2008;132(6):1263-1271.
80. Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas. Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J. 2008;55(1):49-55.
81. Schmitt A, Sarfarzani P, Schmid S, et al. IGFBP and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology. 2006;49(3):298-307.
82. Duregon E, CappelloS E, Maffei V, et al. Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma. Hum Pathol. 2017;52:1-7.
83. Thompson LD. Pheochromocytoma of the Adrenal gland Scattered Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunohistochemical study of 100 cases. Am J Surg Pathol. 2002;26(5):551-566.
84. Wu D, Tischler AS, Lloyd RV, et al. Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scattered Score. Am J Surg Pathol. 2005;29(4):599-608.
85. Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14(4):1505-14.
86. Koh JM, Ahn SH, Kim H, et al. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PloS One. 2017;12(11):e0187398.
87. Kamilaris CDC, Stratakis CA. An update on adrenal endocrinology: significant discoveries in the last 10 years and where the field is heading in the next decade. Hormones (Athens). 2018;17(4):479-490.
88. Reznik Y, LefevreB H, Rohmer V, et al.; REHOS study group. Ablaurant adrenal sensitivity to multiple ligands in unilateral incidentaloma with sub-clinical autonomous cortisol hypersecretion: a prospective clinical study. Clin Endocrinol (Oxf). 2004;61(3):311-319.
89. Lamporn A, Bourdeau I, Obibe S, et al. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteroneoma. J Clin Endocrinol Metab. 2009;94(3):756-756.
90. Allolio B, Fassnacht M. Critical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91(6):2073-2077.
91. NgL, BirrerM W. Adrenocortical carcinoma diagnosis, evaluation and treatment. J Urol. 2003;169(5):15-11.
92. Crucitti F, Bellantone R, Ferrante A, Becchini M, Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiminstitutional series of
129. Schteingart DE, Giordano TJ, Benitez RS, et al.

131. Schteingart DE, Giordano TJ, Benitez RS, et al.

129. Icard P, Goudet P, Charpenay C, et al. Adrenocortical tumors: a review of the literature. J Clin Endocrinol Metab 2014;99(10):E2093-2100.

134. Lindholm J, Juul S, Jørgensen JO, et al. Incidence of renal neoplasms in children and young adults. J Pediatr. 2000;137(3):497-501.

132. Hough AJ, Hollifield JW, Page DL, Hartmann WH. Adrenocortical carcinoma: a novel clinical syndrome. J Clin Endocrinol Metab. 2001;86(1):398-397.

130. Icard P, Goudet P, Charpenay C, et al. Adrenocortical tumors: a review of the literature. J Clin Endocrinol Metab 2014;99(10):E2093-2100.

139. Kim AC, Reuter AL, Zubair M, et al. Targeted disruption of beta-catenin in Sf1-expressing cells impairs gonadotropin-releasing hormone expression and results in female infertility. J Clin Endocrinol Metab 2011;96(6):E1501-E1509.

140. Polakis P. Wnt signaling and cancer. Nat Rev Cancer 2000;1(4):169-186.

141. Reedijk J, van Straten E, van de Wetering M, et al. Identification of novel genetic variants in phospho-purinergic purinergic receptors and their regulatory subunit type 1A of cyclic adenosine monophosphate (cAMP) in hereditary nonsecreting tumors: a study in cortisol-secreting aldosterone-producing adenomas and primary aldosteronism. J Clin Endocrinol Metab 2016;101(9):3526-3538.

143. Ronchi CL, Dalmazi G, Faillot S, et al.; European Pediatric Adrenal Tumor Consortium (EUPATOC). Genetic landscape of sporadic unilaterial macronodular adrenal hyperplasia: clinical and functional correlates. J Clin Endocrinol Metab 2016;101(9):3526-3538.

146. Gicquel C, Bertrand X, Gavon V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2003;61(18):6762-6767.

144. Bertherat J, Horvath A, Groussin L, et al. Mutations in regulatory subunit type 1A of cyclic adenosine monophosphate-dependent protein kinase (PRKACA) phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab 2002;87(12):5367-5384.

149. Horvath A, Boikos S, Giatzakis C, et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 2006;38(7):794-800.

135. Zennaro MC, Boulkroun S, Fernandes-Rosa F, et al. Genetic causes of functional adrenocortical overexpression of CXC chemokines by an adenocortical adenoma with adrenocortical hyperplasia: a genetic and functional analysis of PRKACA and PRKAR1A and its role in regulatory subunit type 1A of cyclic adenosine monophosphate in hereditary nonsecreting tumors: a study in cortisol-secreting aldosterone-producing adenomas and primary aldosteronism. J Clin Endocrinol Metab 2011;96(6):E1501-E1509.

150. Rothenbuhler A, Horvath A, Libé R, et al. Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a CAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. J Clin Endocrinol Oxf 2012;7:195-199.

151. Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012;59(3):592-597.

152. Zheng FF, Zhu LM, Nie AF, et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma. Hypertension 2015;65(3):622-628.

153. Feloua SJ, Kasu K, Lee K, et al. Chinese patients with primary aldosteronism. J Clin Endocrinol Metab 2015;100(7):2401-2409.

154. Åkerström T, Crona J, Delgado Verdugo A, et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. J Clin Endocrinol Metab 2014;99(10):E2093-2100.

155. Zennaro MC, Boulkroun S, Fernandes-Rosa F, et al. Genetic causes of functional adrenocortical overexpression of CXC chemokines by an adenocortical adenoma with adrenocortical hyperplasia: a genetic and functional analysis of PRKACA and PRKAR1A and its role in regulatory subunit type 1A of cyclic adenosine monophosphate in hereditary nonsecreting tumors: a study in cortisol-secreting aldosterone-producing adenomas and primary aldosteronism. J Clin Endocrinol Metab 2011;96(6):E1501-E1509.
Study Group. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459-1466.

180. Lenders JW, DuH QY, Eisenhofer G, et al; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;99(6):1915-1942.

181. Eisenhofer G, Lenders JW, Timmers H, et al. Measurements of plasma metahydroxymine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2013;57(3):611-620.

182. Rosenberg SA, Diamond HD, Jaliloei B, Craver LF. Lymphoma/pleuro: a review of 1269 cases. Medicine (Baltimore). 1996;75(6):318-94.

183. Singh D, Kumar L, Sharma A, Vijayaraghavan M, Velmurugan V, et al. CT pattern of low density pheochromocytoma on CT: a multicenter study. Eur J Radiol. 2018;99(2):330-2.

184. Boland GW, Gorodski CA, Blomqvist F, Ambrogio AG, De Martin M, Fatsi LM, Scacchi M, Cavagnini F. Specificity of first-line tests for the diagnosis of Cushing’s syndrome: an assessment in a large series. J Clin Endocrinol Metab. 2007;92(11):4123-4129.

185. Ferreira L, Oliveira JC, Palma I. Screening tests for hypercortisolism in patients with possible Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(9):3121-3131.

186. Terzolo M, Bovo S, Remondo G, et al. Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am. 2005;34(2):423-39, x.

187. Canu L, Van Hemert JAW, Kerstens MN, et al. CT measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2002;48(1):62-72.

188. Kassim TA, Clarke DD, Mai VQ, Clyde PW, Canu L, Van Hemert JAW, Kerstens MN, et al. CT pattern of low density pheochromocytoma on CT: a multicenter study. Eur J Radiol. 2018;99(2):330-2.

189. Blake MA, Krishnamoorthy SK, Roland GV, et al. Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. AJR Am J Roentgenol. 2003;181(1):1663-1668.

190. Stolk R, Balx C, Mulder J, Timmers HJ, Lenders JW. Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamine overproduction? J Clin Endocrinol Metab. 2011;96(3):1100-1106.

191. Zelinka T, Petrik O, Turková H, et al. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res. 2012;44(5):379-384.

192. Eisenhofer G, Pacak K, Huytt NH, et al. Catecholamine metabolic and secretory phenotypes in pheochromocytoma. Endocr Relat Cancer. 2011;18(1):197-111.

193. Därr R, Kuhn M, Bode C, et al. Analysis of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine. 2017;56(3):495-503.

194. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427-1434.

195. Eisenhofer G, Liddle P, Herberg M, et al. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of pheochromocytoma. Ann Clin Biochem. 2013;50(Pt 1):62-69.

196. Eisenhofer G, Prebisch A, Petsch M, et al. Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites. Clin Chem. 2016;64(1):1666-1666.

197. Epstein JH, Sebti S. Phaeochromocytomas as a cause of hypotension. J Pediatr. 1999;135(1):14-17.

198. Terzolo M, Bovio S, Remondo G, et al. Subclinical Cushing’s syndrome in adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res. 1996;22(4):757-761.

199. Fernández-Real JM, Engeli WR, Simó R, Salinas L, Webb MM. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma. Clin Endocrinol (Oxf). 1998;49(3):153-61.

200. Zelinka T, Petrik O, Turková H, et al. High incidence of cardiovascular complications in pheochromocytoma. J Clin Endocrinol Metab. 2002;87(11):4872-4878.

201. Debono M, Bradburn M, Bull M, Harrison B, Ross RI, Newell-Price J. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab. 2014;99(12):4462-4470.

202. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("Incidentaloma"). Ann Intern Med. 2003;138(5):426-429.
231. Valli N, Catargi B, Ronic N, et al. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Eur J Endocrinol. 2001;144(4):401-408.

232. Raff H, Raff JL, Findling JW. Late-night salivary cortisol: a screening test for Cushing’s syndrome. J Clin Endocrinol Metab. 1998;83(12):4268-4268.

233. Palmieri S, Morelli V, Polledri E, et al. The role of salivary cortisol measured by liquid chromatography-tandem mass spectrometry in the diagnosis of subclinical hypercortisolism. Eur J Endocrinol. 2013;168(3):289-296.

234. Zarkly RK, Anns L, Faiman C, et al. Diagnostic characteristics of late-night salivary cortisol using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2018;103(10):4555-4559.

235. Masserini B, Morelli V, Bergamaschi S, et al. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur J Endocrinol. 2009;160(1):87-92.

236. Denney MC, Annamala AK, Prankerd-Smith O, et al. Low DHEAS: a sensitive and specific test for the detection of subclinical hypercortisolism in adrenal incidentalomas. J Clin Endocrinol Metab. 2017;102(10):3862-3872.

237. Masjkur J, Gruber M, Peitzsch M, et al. Steroid profiling by LC-MS/MS in nonsecreting and subclinical hypercortisol adenomas. J Clin Endocrinol Metab. 2015;100(9):3529-3538.

238. Perysinakis I, Marakaki C, Avlonitis S, et al. Laparoscopic adrenalecctomy in patients with subclinical Cushing’s syndrome. Surg Endosc. 2013;27(6):2145-2148.

239. Iacobone M, Citton M, Violg G, et al. Adrenalectomy may improve cardiovascular and metabolic impair-ment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing’s syndrome. Surgery. 2012;152(6):991-997.

240. Maehana T, Tanaka T, Itoh N, Masunomi S, Tsukamoto T. Clinical outcomes of surgical treatment and longitudinal non-surgical observation of patients with subclinical Cushing’s syndrome and nonfunctioning adrenocortical adenoma. Indian J Urol. 2012;28(2):179-183.

241. Guerrieri M, Campagnacci R, Patrizi A, Romiti C, Araldi G, Bosciano M. Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation. Surg Endosc. 2010;24(10):2542-2546.

242. Chiodini L, Vanicher CE, Morelli V, et al. Mechanisms in endocrinology: endogenous sub- clinical hypercortisolism and bone: a clinical review. Eur J Endocrinol. 2016;175(5):R265-R282.

243. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiaf F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg. 2009;249(3):388-391.

244. Salcuni AS, Morelli V, Eiller Vanicher C, et al. Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism. Eur J Endocrinol. 2016;174(3):261-269.

245. Iacobone M, Citton M, Scarpia M, Violg G, Bosciana M, Nitti D. Systematic review of surgical treatment of adrenal incidentalomas. J Endocrinol Surg. 2015;2015(4):318-330.

246. Hardy RS, Zhou H, Seibel MJ, Cooper MS. Glucocorticoids and bone: consequences of en-dogenous and exogenous excess and replacement therapy. Endocr Rev. 2018;39(5):519-548.

247. Torlontano M, Chiodini I, Fleri M, et al. Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclini- cal hypercortisolism. J Clin Endocrinol Metab. 1999;84(7):2381-2385.

248. Sartorio A, Conti A, Ferro S, et al. Evaluation of markers of bone and collagen turnover in patients with active and preclinical Cushing’s syndrome and in patients with adrenal incidentaloma. Eur J Endocrinol. 1998;139(2):146-152.

249. Francucci CM, Pantanetti P, Garraga GP, Massi F, Araldi G, Mantoro F. Bone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma. Clin Endocrinol (Oxf). 2002;57(3):587-593.

250. Hadjidakis D, Tsagarakis S, Roboti C, et al. Does subclinical hypercortisolism adversely affect the bone mineral density of patients with ad-renal incidentalomas? Clin Endocrinol (Oxf). 2005;63(1):72-77.

251. Osella G, Reimondo G, Penetti P, et al. The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteo- porosis. J Clin Endocrinol Metab. 2001;86(2):604-607.

252. Chiordini L, Morelli V, Masserini B, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas and with subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab. 2009;94(9):3207-3214.

253. Tauchmannová L, Pivonello R, De Martino MC, et al. Effects of sex steroids on bone in women with sub-clinical or overt endogenous hypercortisolism. Eur J Endocrinol. 2007;157(3):359-366.

254. Tauchmanová L, Rossi R, Nuovo V, et al. Bone loss determined by quantitave ultrasonmetry correlates inversely with disease activity in patients with endogenous glucocorticoid excess due to ad-renal mass. Eur J Endocrinol. 2001;145(3):241-247.

255. Perogamvros I, Vassiladi DA, Karpouziou O, Bocoula E, Tzanela M, Tsagarakis S. Biochemical and clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism and bilateral adrenal incidentalomas. Eur J Endocrinol. 2015;173(6):719-725.

256. Goh Z, Phillips I, Hunt PJ, Soule S, Cawood TJ. Three-year follow-up of adrenal incidentalomas in a New Zealand centre. Intern Med J. 2002;30(5):350-356.

257. Elhassan YS, Alahdab F, Prete A, et al. Natural his-tory of adrenal incidentalomas with and without mild autonomous cortisol excess: a system-atic review and meta-analysis. Ann Intern Med. 2019;171(2):107-116.

258. Stavropoulos K, Imprialis KI, Kasiki N, et al. Primary aldosteronism in patients with ad-renal incidentaloma: is screening appropriate for everyone? J Clin Hypertens (Greenwich). 2018;20(5):942-948.

259. Bernini G, Moretti A, Argenio G, Salvetti A. Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur J Endocrinol. 2002;146(6):523-529.

260. Markou A, Pappa T, Kaltas G, et al. Evidence of pri-mary aldosteronism in a predominantly female co-hort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab. 2013;98(4):1409-1416.

261. Matalon V, Venable SV, Tingmar L, et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a compar-ision with hypertensive cases. Clin Endocrinol (Oxf). 2008;69(1):20-28.

262. Moradi S, Shahpeour M, Amirbagho A. A woman with normotensive primary hyperaldosteronism. Acta Med Iran. 2016;54(2):156-158.

263. Young WF. Primary aldosteronism: rena-scence of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607-618.

264. Mulato P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2006;91(8):3045-3050.

265. Rossi GP, Bernini G, Calumini C, et al.; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-2300.

266. Monticone S, D’Ascanio F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hyper-tension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(1):41-50.

267. Hunderme GL, Cufan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mor-tality in medically treated primary aldosteronis-
291. Dinnes J, Bancos I, Ferrante di Ruffano L, et al.
290. NIH state-of-the-science statement on management of adrenal incidentalomas: a debate on patients follow-up. Ann Endocrinol (Paris). 2018;79(4):45-48.
289. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism and incident hypertension: a cohort study. J Clin Endocrinol Metab. 2016;101(5):1889-1916.
288. Brown JM, Robinson-Cohen C, Luque-Fernandez MA, et al. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study. Am J Hypertens. 2017;30(9):630-641.
287. Kamenecky P, Houdoun L, Fericito S, et al. Benign cortisol-secreting adenocortical adenomas produce small amounts of androgens. Clin Endocrinol (Oxf). 2007;66(6):778-788.
286. Fassnacht M, Libé R, Knaiss L, Aliollo B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol. 2017;13(6):323-335.
285. Moreno S, Guillermo M, Decouk M, Dewally D, Bresson R, Proye Ch. Feminizing adrenocortical carcinomas in male adults. A dire prognosis. Three cases in a series of 801 adenalectomies and review of the literature. Ann Endocrinol (Paris). 2006;67(3):32-38.
284. Funder JW, Carey RM, Mantero F, et al. The functional status of incidentally discovered bilateral adrenal incidentalomas. Clin Endocrinol (Oxf). 2011;75(1):44-49.
283. De Venanzi A, Alencar GA, Bourdeau I, Fragoso MC, Lacroix A. Primary bilateral macronodular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obstet. 2014;21(3):177-184.
282. El Borahy N, Bourdeau I, Lacroix A. Multiple aberrant hormone receptors in Cushing's syndrome. Eur J Endocrinol. 2015;173(6):E495-M60.
281. Bourdeau I, El Borahy N, Gagnon N, Lacroix A. Management of endocrine disease: differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas. Eur J Endocrinol. 2018;179(5):R567-R77.
280. Perchiazzi D, Nathan M, Wagner TL. Evidence-based management of incidental focal uptake on fluorodeoxyglucose PET-CT. Br J Radiol. 2018;91(1084):20170771.
279. Del Monte P, Bernasconi D, Bertolazzi L, et al. Increased 17 alpha-hydroxyprogesterone response to ACTH in silent adrenal adenoma: cause or effect? Clin Endocrinol (Oxf). 1995;43(3):273-277.
278. Osswald A, Quinkler M, Di Dalmazzoi G, et al. Long-term outcome of primary bilateral macronodular adrenocortical hyperplasia after unilateral adrenalectomy. J Clin Endocrinol Metab. 2019;104(7):2985-2993.
277. Ierardi AM, Petrillo M, Patella F, et al. Interventional radiology of the adrenal glands: current status. Gland Surg. 2016;5(7):147-165.
276. Bancos I, Tammela S, Shah M, et al. Diagnosis of endocrine disease: the diagnostic performance of adrenal biopsies. J Endocrinol Invest. 2010;33(12):100-109.
275. Gaujoux S, Mihai V, Rijntjes G, et al. Imaging-guided adrenal and renal biopsy. Tech Vasc Interv Radiol. 2010;13(2):100-109.
274. Sherlock et al. Adrenal Incidentaloma. Endocrine Reviews, December 2020, 41(6):1-46.
Bancos, A. R. W. Diagnosis of a malignant adrenal mass: the role of urinary steroid metabolite profiling. Curr Opin Endocrinol Diabetes Obes. 2017;24(2):200-207.

Chorisi V, Bancos I, Nijman T, et al. Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma. J Endocrinol Metab 2020;105(3):e307-e318.

Schweitzer S, Kunz M, Kurlbaum M, et al. Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. Eur J Endocrinol. 2019;180(1):177-182.

Taylor DR, Ghatoae I, Coughlan M, et al. A 13-steroid panel based on LC-MS/MS use in detection of adrenocortical carcinoma. Clin Chem. 2017;63(2):1836-1846.

Lippert J, Appenzeller S, Liang R, et al. Targeted molecular analysis of adrenocortical carcinoma: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab. 2018;103(12):e2906-e2915.

Jain A, Anise G, Libe R, et al. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. J Clin Endocrinol Metab. 2017;102(9):2923-2932.

Zheng S, Cherniack AD, Dewal N, et al. Cancer Genome Atlas Research Network: Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;30(7):723-736.

Sarkar SD, Cohen EL, Beerwinkle WH, Ice RD, Cooper R, Gold EN. A new and superior adrenal imaging agent, 131I-betamethiodiol-19-nor-steroid (NP-59): evaluation in humans. J Clin Endocrinol Metab. 1977;45(2):353-362.

Yen RF, Wu VC, Liu KL, et al. J Clin Endocrinol Metab. 2013;98(7):2827-2833.

Jainor A, Avisse G, Libe R, et al. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. J Clin Endocrinol Metab. 2017;102(9):923-932.

Maiho S, Taylor AE, Biehl M, et al. Urine steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. J Endocrinol Metab. 2020;105(3):e307-e318.

Lippert J, Appenzeller S, Liang R, et al. Targeted molecular analysis of adrenocortical carcinoma: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab. 2018;103(12):e2906-e2915.

Jainor A, Anise G, Libe R, et al. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. J Clin Endocrinol Metab. 2017;102(9):2923-2932.

Chorisi V, Bancos I, Nijman T, et al. Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma. J Endocrinol Metab 2020;105(3):e307-e318.

Schweitzer S, Kunz M, Kurlbaum M, et al. Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. Eur J Endocrinol. 2019;180(1):177-182.

Taylor DR, Ghatoae I, Coughlan M, et al. A 13-steroid panel based on LC-MS/MS use in detection of adrenocortical carcinoma. Clin Chem. 2017;63(2):1836-1846.

Lippert J, Appenzeller S, Liang R, et al. Targeted molecular analysis of adrenocortical carcinoma: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab. 2018;103(12):e2906-e2915.

Jainor A, Avisse G, Libe R, et al. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. J Clin Endocrinol Metab. 2017;102(9):2923-2932.

Zheng S, Cherniack AD, Dewal N, et al. Cancer Genome Atlas Research Network: Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;30(7):723-736.

Sarkar SD, Cohen EL, Beerwinkle WH, Ice RD, Cooper R, Gold EN. A new and superior adrenal imaging agent, 131I-betamethiodiol-19-nor-steroid (NP-59): evaluation in humans. J Clin Endocrinol Metab. 1977;45(2):353-362.

Yen RF, Wu VC, Liu KL, et al. J Clin Endocrinol Metab. 2013;98(7):2827-2833.

Jainor A, Avisse G, Libe R, et al. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. J Clin Endocrinol Metab. 2017;102(9):2923-2932.

Maiho S, Taylor AE, Biehl M, et al. Urine steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. J Endocrinol Metab. 2020;105(3):e307-e318.

Lippert J, Appenzeller S, Liang R, et al. Targeted molecular analysis of adrenocortical carcinoma: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab. 2018;103(12):e2906-e2915.

Jainor A, Avisse G, Libe R, et al. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. J Clin Endocrinol Metab. 2017;102(9):2923-2932.
384. Yi X, Guan X, Chen C, et al. Adrenal incidentaloma: machine learning-based quantitative texture analysis of unenhanced CT can effectively differentiate sPHEO from lipid-poor adrenal adenoma. J Cancer. 2018;9(19):3577-3582.

Acknowledgments

Financial Support: National Institute for Health Research (Senior Fellowship) Paul M. Stewart.

Additional Information

Correspondence and Reprint Requests: Professor Paul M Stewart, University of Leeds, Room 9.14, Worsley Building, Clarendon Way, Leeds LS2 9NL, UK. E-mail: p.m.stewart@leeds.ac.uk

Disclosure Summary: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. I certify that neither I nor my co-authors have a conflict of interest as described above that is relevant to the subject matter or materials included in this Work.

Data Availability: All data generated or analyzed during this study are included in this published article or in the data repositories listed in References.

Abbreviations

17-OHP, 17-hydroxyprogesterone; ACA, adrenocortical adenoma; ACC, adrenocortical carcinoma; ACS, autonomous cortisol secretion; ACTH, adrenocorticotropin; AI, adrenal incidentaloma; BMI, body mass index; CAH, congenital adrenal hyperplasia; cAMP, 3,5’-cyclic adenosine 5’-monophosphate; COMT, catechol-O-methyltransferase; CT, computed tomography; DHEA, dehydroepiandrosterone; DHEAS, DHEA sulfate; FDG, 18-fluorodeoxyglucose; GC-MS, gas chromatography-mass spectrometry; HPA, hypothalamic–pituitary–adrenal; HU, Hounsfield units; LC-MS/MS, liquid chromatography-tandem mass spectrometry; MACE, mild autonomous cortisol excess; MEN, multiple endocrine neoplasia; MRI, magnetic resonance imaging; MTO, metomidate; NF1, neurofibromatosis type 1; NFAT, nonfunctioning adrenal tumor; PA, primary aldosteronism; PET, positron emission tomography; PKA, protein kinase A; PBMAH, primary bilateral macronodular adrenal hyperplasia; SPECT-CT, single-photon emission computed tomography-computed tomography; SUV, standardized uptake value; TH, tyrosine hydroxylase; THS, tetrahydro-11-deoxycortisol; UFC, urine free cortisol; VHL, Von Hippel Lindau